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5Foreword
It gives me particular pleasure to present the results of the risk assessment
undertaken by the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA) on three substances: 2C-I (2,5-dimethoxy-4-iodophenethylamine), 
2C-T-2 (2,5-dimethoxy-4-ethylthiophenethylamine) and 2C-T-7 (2,5-dimethoxy-4-(n)-
propylthiophenethylamine). The risk assessment was carried out under the terms of
a joint action adopted on 16 June 1997 by the Council of the European Union (1).
The meeting to assess the risks of 2C-I, 2C-T-2, 2C-T-7 was convened under the
auspices of the Scientific Committee of the EMCDDA and was held on 31 March
and 1 April 2003 at the Centre’s headquarters in Lisbon. The meeting produced
formal reports on the risk assessments, which were adopted the same day. As
foreseen in the joint action, the reports were submitted without delay to the
European Commission and to the Greek Presidency of the horizontal working
party on drugs (HWPD) of the Council of the EU for further action.
As a result, on 27 November 2003,  the Council adopted the decision (2) to submit
2C-I, 2C-T-2 and 2C-T-7 to control measures and criminal penalties in the 15 EU
countries. The Council decision stipulates that, within three months, Member States
shall introduce the necessary measures into their national law, in compliance with
their obligations under the 1971 United Nations Convention on Psychotropic
Substances.
Such a concrete result at a political level confirms the effectiveness of the rapid-
response mechanism provided by the joint action on new synthetic drugs. It is also
encouraging to see the strong cooperation that has developed over the last years
between the EMCDDA and its institutional partners involved in the risk assessment
process, including the European Police Office (Europol), the European Agency for
the Evaluation of Medicinal Products (EMEA) and the European Commission. In
particular, I would like to underline the excellent work done by the EMCDDA’s
early-warning system via the Reitox network of national focal points and through
Europol’s national units. The dedication of all partners will be crucial in the
Foreword
(1) Joint action concerning the ‘information exchange, risk assessment and the control of new synthetic drugs’ (OJ L 167,
25.6.1997). A joint action is a decision adopted unanimously by the EU Member States within the framework of the
third pillar of the Treaty on European Union (cooperation in the field of justice and home affairs). Synthetic drugs are
psychoactive substances produced in laboratories and not derived from natural products. They include 3,4-
methylenedioxy-N-methylamphetamine (MDMA, ‘ecstasy’), other amphetamines and lysergic acid diethylamide (LSD).
(2) OJ L 321, 6.12.2003, pp. 64–65.
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successful implementation of the new Council decision proposed by the
Commission to replace the 1997 joint action on new synthetic drugs. This initiative
is directly related to the outcome of the external evaluation of the joint action
undertaken by the Commission as stipulated by the European Union action plan on
drugs 2000–04. The new legal instrument aims to clarify the definitions and
procedures and extend the scope to all new synthetic drugs and all new narcotic
drugs alike.
I would like to thank all those who participated in the risk assessment process for
2C-I, 2C-T-2 and 2C-T-7 for the high quality of the work carried out. This makes a
valuable scientific contribution, validated at a European level, and, as such, gives
proven support to political decision-making.
Georges Estievenart
Executive Director, EMCDDA
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Abbreviations 
2C-B 2,5-dimethoxy-4-bromophenethylamine
2C-H 2,5-dimethoxyphenethylamine
2C-I 2,5-dimethoxy-4-iodophenethylamine
2C-T 2,5-dimethoxy-4-methylthiophenethylamine
2C-T-2 2,5-dimethoxy-4-ethylthiophenethylamine
2C-T-7 2,5-dimethoxy-4-(n)-propylthiophenethylamine
ACTH adrenocorticotrophic hormone
ALEPH-2 2,5-dimethoxy-4-ethylthioamphetamine
bpm beats per minute
DOB 2,5-dimethoxy-4-bromoamphetamine
DOM 2,5-dimethoxy-4-methylamphetamine
GHB gamma-hydroxybutyrate
5-HT 5-hydroxytryptamine (serotonin)
i.p. intraperitoneal
i.m. intramuscular
i.v. intravenous
LSD lysergic acid diethylamide
MAO monoamine oxidase
Mescaline 3,4,5-trimethoxyphenethylamine
MDMA 3,4-methylenedioxy-N-methylamphetamine
4-MTA 4-methylthioamphetamine
SSRI selective serotonin reuptake inhibitor
TMA-2 2,4,5-trimethoxyamphetamine
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Introduction
Since the adoption by the Council in June 1997 of the joint action on the
information exchange, risk assessment and control of new synthetic drugs, 2C-I
(2,5-dimethoxy-4-iodophenethylamine), 2C-T-2 (2,5-dimethoxy-4-
ethylthiophenethylamine) and 2C-T-7 (2,5-dimethoxy-4-(n)-
propylthiophenethylamine) are the sixth, seventh and eighth substances to be
subjected to risk assessment.
2C-I, 2C-T-2 and 2C-T-7 are among the numerous ‘new synthetic drugs’ with no
legitimate therapeutic use that are described in Shulgin’s Pihkal (Shulgin and
Shulgin, 1991). All three compounds have the structural characteristics of
phenethylamines, which are associated with stimulant and hallucinogenic actions
and, therefore, seem to be comparable to substances already classified in the
schedules of the 1971 United Nations Convention on Psychotropic Substances,
such as 2C-B (4-bromo-2,5-dimethoxyphenethylamine, as listed in Schedule II).
The specific scientific risk assessments of 2C-I, 2C-T-2 and 2C-T-7 have been
extremely difficult due to the lack of peer-reviewed scientific data. However,
information based on analogy to partially related compounds such as 2C-B
(phenethylamine-based) and DOB (amphetamine-based), both involving bromine
as opposed to sulphur, as well as evidence from other information sources such as
individual user reports, provided the basis for the assessments. It is worth noting
that it was deemed inappropriate to compare data derived from MDMA, PMA and
4-MTA studies, because of the absence of 2,5-dimethoxy substituent groups in
these compounds.
An overview of the pharmacology, toxicology, clinical experience and individual
health and psychological risks of 2C-I, 2C-T-2 and 2C-T-7 use was compiled by
Simon Elliott, Senior Clinical Scientist at the Regional Laboratory for Toxicology,
Birmingham. This overview was further extended by a review, completed by the
EMCDDA and Europol, on the pharmacotoxicological, sociological and
criminological information available about the three substances.
The members of the Scientific Committee of the EMCDDA, extended with experts
nominated by the Member States and representatives of the European Commission,
Europol and the EMEA, met in Lisbon on 31 March 2003 to examine the health
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and social risks of 2C-I, 2C-T-2 and 2C-T-7 as well as the possible consequences
of prohibition. The conclusions and recommendations of the risk assessment
reports were prepared and adopted on 1 April 2003. Based on the conclusions of
the reports, the Council decided to adopt a decision making 2C-I, 2C-T-2 and 2C-
T-7 the subject of control measures in the EU Member States, as provided for
under Schedules I and II of the 1971 UN Convention on Psychotropic Substances.
In the light of the risk assessments carried out since 1998, the Scientific
Committee’s sub-committee on synthetic drugs came to the following conclusions:
the decision to have a molecule assessed often implies a lack of scientific data
about its toxicity as well as its dependence potential or its implication in social
disturbances; however, lack of scientific data does not guarantee that the molecule
is not harmful. A principle of precaution should therefore be the rule when only
limited data are available.
The Scientific Committee of the EMCDDA is aware of how difficult it is to obtain
scientific data on a new drug and is currently reflecting, in the framework of its
sub-committee on synthetic drugs, on the possibility of proposing an emergency
temporary scheduling of the identified substance in order to allow time for
collecting sufficient scientific information. However, such a proposal could only be
discussed within the perspective of a new Council decision modifying the current
joint action on new synthetic drugs. Meanwhile, despite its limitations, the
provisions of Article 4 of the joint action have been implemented for the risk
assessment of 2C-I, 2C-T-2 and 2C-T-7.
As Chairperson and Vice-Chairperson of the Scientific Committee, we would like
to express our gratitude to our colleagues on the Scientific Committee as well as to
the staff of the EMCDDA, in particular Alain Wallon, Lena Westberg, Deborah
Olszewski and Roumen Sedefov, who worked hard before, during and after the
meetings to finalise the reports in order to provide detailed and precise
conclusions and ensure a speedy completion of the project. We hope that all these
efforts will be appreciated by those to whom this report is addressed.
Salme Ahlström and Jean-Pol Tassin
Chairperson and Vice-Chairperson, Scientific Committee of the EMCDDA


Council decision
Council decision
Council Decision 2003/847/JHA of 27 November 2003 concerning
control measures and criminal sanctions in respect of the new synthetic
drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty of the European Union,
Having regard to Council Joint Action 97/396/JHA of 16 June 1997 concerning
the information exchange, risk assessment and the control of new synthetic drugs (3),
and in particular Article 5(1) thereof,
Having regard to the initiative of the Italian Republic,
Whereas:
(1) Risk assessment reports on 2C-I (2,5-dimethoxy-4-iodophenethylamine), 2C-T-2
(2,5-dimethoxy-4-ethylthiophenethylamine), 2C-T-7 (2,5-dimethoxy-4-(n)-
propylthiophenethylamine) and TMA-2 (2,4,5-trimethoxyamphetamine) were
drawn up on the basis of Article 4(3) of Joint Action 97/396/JHA at a
meeting convened under the auspices of the Scientific Committee of the
European Monitoring Centre for Drugs and Drug Addiction.
(2) 2C-I, 2C-T-2, 2C-T-7 and TMA-2 are amphetamine derivatives having
structural features of phenethylamines, which are associated with
hallucinogenic and stimulant activity. 2C-I, 2C-T-2, 2C-T-7 and TMA-2 have not
been reported to be associated with fatal or non-fatal intoxication within the
Community. However, 2C-I, 2C-T-2, 2C-T-7 and TMA-2 are hallucinogenic
drugs that carry potential risks common to other hallucinogenic substances
such as 2C-B, DOB, TMA and DOM, already classified in Schedules I or II to
the 1971 United Nations Convention on Psychotropic Substances. Therefore a
risk of acute or chronic toxicity cannot be excluded.
(3) 2C-I, 2C-T-2, 2C-T-7 and TMA-2 are not currently listed in any of the schedules
to the 1971 United Nations Convention on Psychotropic Substances.
15
(3) OJ L 167, 25.6.1997, p. 1.
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(4) At present, 2C-I and 2C-T-2 are controlled under the national drugs legislation
in five Member States; 2C-T-7 and TMA-2 are controlled in four Member
States.
(5) 2C-I, 2C-T-2, 2C-T-7 and TMA-2 have no therapeutic value or industrial use.
(6) 2C-I has been identified in four Member States; 2C-T-2 and 2C-T-7 have been
identified in six Member States; TMA-2 has been identified in five Member
States. At present one Member State has reported one case of international
trafficking of 2C-T-2 involving two Member States; no international trafficking
of 2C-I, 2C-T-2 and TMA-2 has been reported. Laboratories involving the
production of 2C-I, 2C-T-2, 2C-T-7 and TMA-2 have been seized in three
Member States. In one of these Member States, the seizure of a large amount
of the intermediate precursor 2C-H and documentation suggests the production
of 2C-I. The major chemical precursors of 2C-I, 2C-T-2, 2C-T-7 and TMA-2 are
commercially available.
(7) 2C-I, 2C-T-2, 2C-T-7 and TMA-2 should be subjected by the Member States to
control measures and criminal penalties, as provided for under their legislation
complying with their obligations under the 1971 United Nations Convention on
Psychotropic Substances with respect to substances listed in Schedules I or II
thereto,
HAS DECIDED AS FOLLOWS:
Article 1
Member States shall take the necessary measures, in accordance with their
national law, to submit 2C-I (2,5-dimethoxy-4-iodophenethylamine), 2C-T-2 (2,5-
dimethoxy-4-ethylthiophenethylamine), 2C-T-7 (2,5-dimethoxy-4-
(n)propylthiophenethylamine) and TMA-2 (2,4,5-trimethoxyamphetamine) to control
measures and criminal penalties, as provided for under their legislation complying
with their obligations under the 1971 United Nations Convention on Psychotropic
Substances with respect to substances listed in Schedules I or II thereto.
Article 2
Member States shall, in accordance with the third subparagraph of Article 5(1) of
Joint Action 97/396/JHA, take the measures referred to in Article 1 within three
months of the date on which this decision takes effect.
Council decision
Within six months of the date on which this decision takes effect Member States
shall inform the Secretariat General of the Council and the Commission of the
measures they have taken.
Article 3
This decision shall be published in the Official Journal of the European Union.
It shall take effect on the day following that of its publication.
Done at Brussels, 27 November 2003.
For the Council
The President
R. Castelli
17
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Chapter 1
Report on the risk assessment of 2C-I in the
framework of the joint action on new synthetic
drugs
On 12 December 2002, the horizontal working party on drugs of the Council of the
European Union decided that risk assessment of four new synthetic drugs, 2C-T-2, 
2C-T-7, 2C-I and TMA-2, should be initiated. On 20 December 2002, in accordance
with practice under the 1997 joint action, the Danish Presidency formally notified the
EMCDDA of the decision of the HWPD to submit 2C-T-2, 2C-T-7, 2C-I and TMA-2 for
risk assessment under Article 4 of the joint action on new synthetic drugs of 16 June
1997.
A meeting of the Scientific Committee of the EMCDDA, extended with experts
nominated by the Member States and representatives of the European Commission,
Europol and the EMEA, was held on 31 March to 1 April 2003 to assess the health
and social risks of 2C-I as well as the possible consequences of its prohibition.
The meeting considered the following documents:
i. Review of the pharmacotoxicological data for the risk assessment of 2C-I; report
to the EMCDDA
ii. Public health risks: epidemiological evidence; EMCDDA
iii. Sociological/criminological evidence; EMCDDA
iv. Europol contribution to the risk assessment on 2C-I
In conjunction with further information and comments from the expert participants,
these documents formed the basis of the risk assessment which is reported below.
Chemical description
2C-I is 2,5-dimethoxy-4-iodophenethylamine. Other chemical names include: 4-iodo-
2,5-dimethoxyphenethylamine, (2,5-dimethoxy-4-iodophenyl)-2-aminoethane and 
4-iod-2,5-dimethoxyphenethylazan.
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The synthesis of 2C-I is described in Pihkal (Shulgin and Shulgin, 1991), based on the
initial use of 2,5-dimethoxybenzaldehyde to eventually produce a preliminary
precursor, 2,5-dimethoxyphenethylamine (2C-H). The former compound 2,5-
dimethoxybenzaldehyde is available commercially. The method is extensive, requiring
specialist equipment and an appropriate environment. The exact method of synthesis
used by clandestine laboratories is not known.
At present, 2C-I has no medical or industrial use.
Pharmaceutical description
2C-I is typically available in powder or tablet form, although 2C-I in liquid form has
also been noted by the Danish focal point. A seized tablet was white in appearance,
had an ‘i’ logo and was approximately 6.1 mm x 2.7 mm in size, weighing 120 mg
(Denmark, 2002).
As 2C-I comes in powder or tablet form, the primary route of administration is oral.
Neither insufflation (snorting) nor any other routes (e.g. intravenous administration)
are mentioned in 2C-I user reports. Original studies by Shulgin involved oral
administration of doses of 2C-I of 15 to 20 mg. User reports have mentioned oral
doses of 3 to 25 mg (typically 20 mg).
Health risks
Individual health risks
Acute effects
Little scientific evidence related to the action of 2C-I on neurotransmitter systems has
been published to date, so discussion of the neuropharmacological aspects at the risk
assessment meeting was based on speculative comparison with partially related
compounds such as 2C-B (based on phenethylamine) and DOB (based on
amphetamine), both involving bromine as opposed to iodine.
Studies involving a bromine-substituted analogue, 2C-B (4-bromo-2,5-
dimethoxyphenethylamine), have shown it to be a partial agonist for 5-HT2 (5-HT2A
and 5-HT2C) serotonergic receptors and 1-adrenergic receptors. At 10-6M, 2C-B also
Chapter 1
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acted as a competitive 5-HT antagonist, but, at higher concentrations (2.8 x 10-5M), it
acted as a non-competitive 5-HT antagonist. In addition, DOB (4-bromo-2,5-
dimethoxyamphetamine) was found to have a high affinity for 5-HT2 receptors,
whereas 2C-B was also found to have significant affinity for 5-HT1A, 5-HT1B and
5-HT1C receptors and thus was deemed to be less selective than its amphetamine-
based analogue, DOB.
A recent study found 2C-I to have higher agonistic efficacy at 5-HT2C receptors
compared to 5-HT2A receptors. However, further studies will be required before
definitive conclusions can be drawn.
There has been no other specific research conducted on 2C-I. Serotonin agonists
stimulate hypothalamic neurons involved in ACTH and cortisol secretion, in addition
to stimulating growth hormones and prolactin secretion (as evidenced by mescaline
and DOM). It is possible, therefore, that 2C-I may produce similar effects on
hormonal secretion.
There is also a small amount of subjective evidence available on the Internet
regarding cardiovascular and thermoregulatory responses. However, these user
surveys record a variety of responses to 2C-I use.
At present there are no animal or human data concerning general toxicity,
reproductive toxicity, neurotoxicity or the mutagenicity and carcinogenic potential of
2C-I. Only subjective evidence is available from limited user self-reports involving
observations of some adverse effects and toxic symptoms. In general, although users
have described 2C-I as ‘powerful’ and a ‘strong stimulant’ with hallucinogenic
properties, there is virtually no mention of adverse effects such as nausea, vomiting or
muscle cramps (as reported for 2C-T-2 and 2C-T-7) in users purporting to have taken
only 2C-I. However, the nature of the reports suggests that this may be due to selective
reporting rather than absence of such symptoms. However, some users report stomach
tension, nausea, vomiting and jaw tension in instances of combining 2C-I with one or
more of the following: 5-methoxy-dipropyltryptamine, cannabis, alcohol, caffeine,
tryptophan, alprazolam and clonazepam. It has been noted by users of 2C-I that the
desired effect may be delayed, sometimes resulting in users taking additional
(sometimes higher) doses.
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It appears that, unlike other phenethylamine derivatives (including 2C-B), 2C-I tablets
do not usually contain other phenethylamines or stimulants, thus reducing the
possibility of concomitant ingestion of other drugs in such illicit preparations.
However, as the pharmacology of 2C-I is largely unknown, it is difficult to predict with
accuracy any potential drug interactions or contraindications. Winter et al. studied the
acute effects of monoamine reuptake inhibitors (SSRIs such as fluvoxamine, fluoxetine
and venlafaxine) on the stimulatory effects of hallucinogens (including DOM) and
observed an additivity of effects rather than a potentiation. It is possible, therefore,
that similar effects may occur with 2C-I. Various users report concomitant use with
other drugs but specific evidence is unclear. However, in some cases this has
produced toxic effects (see above).
Anecdotal user evidence indicates the onset of initial action as being one to two hours
after ingestion. However, some users report this as being longer compared to related
drugs (e.g. 2C-B or MDMA). Effects are typically described as lasting for up to 10
hours post oral dose. This compares to eight to 12 hours for orally ingested LSD and
10 to 12 hours for mescaline, as reported by Shulgin.
Clinical effects
There have been no reported deaths or instances of non-fatal intoxication involving 
2C-I. However, as with clinical toxicological investigations, the lack of reference
material may compromise the analysis of post-mortem cases.
There have been no scientific studies involving 2C-I users. Limited subjective user
reports indicate that 2C-I produces various psychedelic effects (generally comparable
to other hallucinogens, particularly 2C-B) and feelings of empathy (similar to MDMA).
Isolated user reports compare 2C-I to 2C-B, due to an apparent similarity in their
effects. However, some users describe the effects of 2C-I as being ‘deeper, more purely
psychedelic and less sensory’ and, in some cases, less intense. As mentioned above,
various users have reported delayed onset of the desired effects compared to related
drugs (e.g. 2C-B or MDMA), which may result in additional doses or other drugs being
taken, thus increasing the risk of toxicity or accidental overdose.
Chapter 1
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Dependence
No specific research has been performed to evaluate the potential of 2C-I to induce
dependency in animals or humans. Although the exact pharmacology of 2C-I is
unknown, speculative comparison with related compounds suggests it is unlikely to
produce physical dependence or addiction. However, without any specific studies,
definitive conclusions cannot be drawn.
Psychological effects
There are no published data on the specific psychological effects, acute or chronic, of
2C-I. As mentioned above, limited anecdotal reports describe the psychological effects
of 2C-I experienced by users. Such reports mention a general clarity of thought, with
little or no ‘psychological after-effects’. However, some introspection and ‘negative
thought-loops’ were described by a number of users.
Public health risks
Availability and quality of 2C-I on the market
2C-I has been identified in four Member States: Denmark, Germany, Sweden and the
United Kingdom.
Information based on early-warning databases suggests that 2C-I is very rare. One
tablet of 2C-I was seized in Denmark. This had an ‘i’ logo and so was probably not
sold to users as ecstasy (MDMA).
Knowledge and perception of 2C-I among users
The level of awareness about 2C-I is generally negligible, except among small
subgroups of experimenters who may use mescaline, DOB or 2C-B for particular
effects. Due to the lack of research studies, the level of knowledge among these
particular consumer subgroups (as can be seen on the Internet) appears to be more
detailed than in the general scientific community. In the absence of accurate and
regulated chemical analysis, objective scientific knowledge remains extremely limited.
Major information sources are Internet sites and ‘dance floor pharmacology’ (an
informal network whereby information passes from friend to friend). Despite warnings
about the potential harm associated with using health information from the Internet, a
systematic search of peer-reviewed literature found few reported cases of harm. This
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may be due to an actual low risk for harm associated with the use of information
available on the Internet, or to under-reporting of cases, or to bias.
Prevalence and patterns of use
Evidence of 2C-I use in the EU is very limited. Population surveys of young adults in
the EU show that a range of 1 % in Finland to 12 % in the United Kingdom have
‘lifetime prevalence’ of hallucinogenic substances, most commonly ‘magic
mushrooms’. School surveys of 15- to 16-year-olds in the EU show that 1 to 5 % of
this age group have used LSD or other hallucinogens, compared to 10 % in the USA
(EMCDDA and ESPAD).
Characteristics and behaviour of users
2C-I users may belong to a very small group of people with a pseudo-scientific
interest in experimenting with hallucinogenic substances, often referred to as
‘psychonauts’. There appears to be a trend among a small but significant minority of
users towards broadening their repertoire of drug experiences, involving a wider
range of drugs and combinations. Special concerns relate to the lack of knowledge
about the drug contents and the specific harmful effects of 2C-I, either alone or in
combination with other drugs.
Indicators of health consequences
Information on the health consequences is limited to an apparently very small
population of users. There is no information available on the long-term consequences
for health of 2C-I use.
Context of use
There is no scientific evidence about the risk factors linked to the circumstances and
consumption practices of 2C-I use.
Social risks
Sociological aspects
Young people outside of the ecstasy-using population are relatively unlikely to come
into contact with 2C-I under present conditions.
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As with all illicit drug use, lack of scientific and objective information contributes
towards increased risk. Firstly, inaccurate media coverage and overestimation of
prevalence may promote diffusion by encouraging young people to try it. Secondly,
official dissemination of inaccurate information is counterproductive, as it can
undermine credibility.
A few more experimental drug users appear to be motivated to use 2C-I by a desire
to experience a wide range of sensations.
Social consequences
There is currently no scientific evidence of negative social consequences. However,
2C-I carries potential risks common to other hallucinogenic substances.
Consequences for the social behaviour of the user
There is no specific evidence to link the use of 2C-I to disorderly conduct, acquisitive
crime or violence. However, the delayed action described by users may have
implications for driving a vehicle and using machinery.
Other social consequences
There is no indication that 2C-I is particularly associated with any major value
conflicts or has any important implications for social institutions beyond those
described for similar compounds.
Criminological aspects
The law enforcement agencies of all 15 Member States reported to Europol that there
is no information available to suggest that there is large-scale production and
distribution of and/or trafficking in 2C-I or that organised crime has any role in these
activities. Belgium and Italy reported that the main reason for the lack of information
is that the substance is not controlled in those countries and, therefore, no records are
kept by the law enforcement agencies.
Germany and Sweden reported that limited quantities of 2C-I were produced in
1999. This related, in both countries, to one case only, involving small ‘kitchen-type’
laboratories.
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Three Member States reported seizures of 2C-I. These were small, both in terms of
numbers and the quantities seized. Denmark reported a seizure, in April 2002, of
one 2C-I tablet, which was sent to a forensic laboratory by a psychiatrist working in
the drug field. Germany reported a seizure, in 1999, of 0.3 gm of 2C-I from a
kitchen-type laboratory in Brannenburg, Bavaria. Sweden reported one seizure, in
1999, of a small amount of 2C-I that was also produced in a kitchen-type laboratory.
No link to organised crime was established.
In 1999, the United Kingdom Reitox focal point reported a small seizure of 2C-I to the
EMCDDA.
Prohibition
Legal status
An analysis of the legal status of 2C-I shows that the drug is controlled in five
Member States. 2C-I is not controlled in the USA.
In Germany, 2C-I was placed under permanent control on 19 June 2001. The
substance had already been controlled on a temporary basis since 1999. The
arguments (outlined in the legal text ‘Fünfzehnte Betäubungsmittelrechts-
Änderungsverordnung-15. BtMÄndV’, of 19 June 2001) for placing these kinds of
drugs under permanent control are as follows: (i) these substances are being used as
ecstasy-type drugs; and (ii) they are produced by illegal laboratories that modify the
chemical structure of illegal drugs in order to avoid the law (‘designer drugs’).
In the United Kingdom, 2C-I comes under the definition of a controlled substance
(Class A) by virtue of a generic description set out in the Misuse of Drugs Act (1977).
In Ireland, 2C-I is a controlled drug under Schedule 1 of the Misuse of Drugs Act, as
a result of the generic control approach.
In Denmark, 2C-I has been controlled since May 2002 (’Bekendtgørelse nr. 305 af
16. maj 2002 om ændring af bekendtgørelse om euforiserende stoffer’).
In Greece, the drug is controlled under Table A of Law 1729/87.
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Possible consequences of prohibition
The meeting acknowledged that 2C-I is already controlled in five Member States. It
was noted that, structurally, 2C-I seems to be comparable to substances already
classified under Schedules I or II of the 1971 United Nations Convention on
Psychotropic Substances. It was also noted that 2C-I has no medical or industrial use.
Arising from the above, it was felt that there is no real alternative to prohibition as a
control measure. It was widely agreed that such measures would enhance the
capacity for detection and monitoring of the drug on the market and limit the
potential for expansion of the supply and use of 2C-I. Another supporting argument
was that exempting 2C-I from legal controls would send an inaccurate message about
the comparative safety of the substance. Increased availability of information about
the drug would also stimulate the gathering and dissemination of analytical
information for public health purposes.
The meeting was also of the opinion that prohibition could engender stigmatisation of
the small self-limiting groups of 2C-I users. It was also felt that the lack of scientific
evidence makes it very difficult to determine the possible consequences of legal
controls on 2C-I.
There was a consensus of opinion that control measures should not prevent the
dissemination of accurate information on 2C-I to users and to relevant professionals
for preventive and harm reduction measures. Marginalisation of 2C-I users should be
avoided.
Conclusions
The Scientific Committee of the EMCDDA, extended with experts from the Member
States and representatives of the Commission, Europol and the EMEA, have
considered the health and social risks as well as the possible consequences of
prohibition of 2C-I and, in accordance with Article 4 of the joint action, submit the
following conclusions.
• 2C-I has the structural characteristics of phenethylamines, which are associated with
stimulant and hallucinogenic activity. This would appear to make it comparable to
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substances already classified in the schedules of the 1971 United Nations
Convention on Psychotropic Substances, such as 2C-B (listed in Schedule II as 
4-bromo-2,5-dimethoxyphenethylamine).
Specific scientific risk assessment of 2C-I is extremely difficult, due to the lack of peer-
reviewed scientific data. However, information based on analogy to 2C-B and DOB
and evidence classified to evidence level IV (4) indicate the following.
• 2C-I is a synthetic drug that was first synthesised by Shulgin.
• Seized/available material includes powder, tablets (white, ‘i’ logo) and liquid
preparations.
• 2C-I has no current medical or industrial use.
• There is confirmed 5-HT2C and 5-HT2A serotonergic receptor agonistic activity and
potential 5-HT1 and 1-adrenergic receptor agonistic activity.
• Users report hallucinogenic/visual effects (similar to 2C-B, LSD and mescaline) and
feelings of empathy (similar to MDMA); however, no scientific data are available.
• Self-reporting users have only mentioned oral ingestion of 2C-I.
• Due to the lack of specific scientific evidence, acute or chronic toxicity has not been
confirmed in humans, but toxic effects cannot be excluded.
• Anecdotal reports from users suggest that 2C-I may have a slower onset of action
than related drugs (e.g. 2C-B or MDMA). This could result in some users taking
additional doses or other drugs, thus increasing the risk of toxicity or overdose.
• There have been no reported cases of fatal or non-fatal intoxication.
• There is currently no scientific evidence of negative social consequences. However,
2C-I carries risks common to other hallucinogenic substances that are already
controlled.
• There is no evidence to suggest that there is large-scale manufacture and trafficking
of 2C-I or that organised crime is implicated.
• 2C-I has been identified in four EU Member States and it is controlled in five.
(4) Refers to the classification of information sources in Guidelines for risk assessment of new synthetic drugs, adopted by
the EMCDDA’s Scientific Committee.
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Recommendations
• The meeting was strongly of the opinion that, due to its hallucinogenic/stimulant
properties and its potential risk to health, 2C-I should be a controlled substance.
However, there were some experts who felt that there was insufficient scientific
evidence to make such a recommendation.
• The meeting also recommended that any decision to place 2C-I under control
should not inhibit the gathering of information about drugs on the market and the
dissemination of accurate information on 2C-I to users and relevant professionals.
• The major chemical precursor of 2C-I, namely 2,5-dimethoxybenzaldehyde, is
available commercially. Should the substance be controlled, the meeting
recommended that the Drug Precursors Committee (set up under Article 10 of
Regulation (EEC) No 3677/90 and Directive 92/109/EEC) should closely examine
the situation regarding this precursor chemical, which is involved in the synthesis of
2C-I and is not yet subject to any surveillance measures.
• The meeting reiterated its earlier recommendation that, when a new synthetic drug
is notified for risk assessment, arrangements be made for the provision of standard
reference materials and associated analytical data to forensic and toxicology
laboratories within the European Union. The meeting further recommended that 
2C-I be included in the UNDCP proficiency-testing programme.
Lisbon, 31 March to 1 April 2003
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Report on the risk assessment of 2C-T-2 in 
the framework of the joint action on 
new synthetic drugs
On 12 December 2002, the horizontal working party on drugs of the Council of the
European Union decided that risk assessment of four new synthetic drugs, 2C-T-2, 
2C-T-7, 2C-I and TMA-2, should be initiated. On 20 December 2002, in accordance
with practice under the 1997 joint action, the Danish Presidency formally notified the
EMCDDA of the decision of the HWPD to submit 2C-T-2, 2C-T-7, 2C-I and TMA-2 for
risk assessment under Article 4 of the joint action on new synthetic drugs of 16 June
1997.
A meeting of the Scientific Committee of the EMCDDA, extended with experts
nominated by the Member States and representatives of the European Commission,
Europol and the EMEA, was held on 31 March 2003 to assess the health and social
risks of 2C-T-2 as well as the possible consequences of prohibition.
The meeting considered the following documents.
i. Review of the pharmacotoxicological data for the risk assessment of 2C-T-2;
report to the EMCDDA
ii. Public health risks: epidemiological evidence; EMCDDA
iii. Sociological/criminological evidence; EMCDDA
iv. Europol contribution to the risk assessment on 2C-T-2
In conjunction with further information and comments from the expert participants,
these documents formed the basis of the risk assessment which is reported below.
Chemical description
2C-T-2 is 2,5-dimethoxy-4-ethylthiophenethylamine. Other chemical names include:
4-ethylthio-2,5-dimethoxyphenethylamine and 4-ethylsulfanyl-2,5-
dimethoxyphenethylazan. The abbreviation ‘2C-T-2’ is derived from the nomenclature
according to Shulgin. Although this compound has less carbons than 2C-T-7, the ‘-2’
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part of the abbreviation has no structural significance. 2C-T-2 hydrochloride is a
white crystalline solid. The synthesis protocol described in Pihkal (Shulgin and
Shulgin) is based on initial use of 1,4-dimethoxybenzene to eventually produce a
preliminary precursor, 2,5-dimethoxythiophenol. Shulgin describes the latter
compound as a ‘valuable precursor to all members of the 2C-T family’ and it is now
commercially available. The abovementioned method requires specialist equipment
and an appropriate environment. Intermediate substances and the final product
according to the Shulgin synthetic methodology for 2C-T-2 were identified in
chemicals/material seized from a clandestine laboratory.
2C-T-2 exhibits a slightly more orange colour using the Marquis reagent assay
compared to a slightly more red colour with 2C-T-7.
At present, 2C-T-2 has no medical or industrial use.
Pharmaceutical description
2C-T-2 is typically available in powder or tablet form. No associated ‘street names’
have been reported specifically relating to 2C-T-2. 2C-T-2 was previously (1997–99)
sold in Dutch smartshops as 2C-T-7 or ‘S5’ (4-MTA). It was also apparently sold in
similar shops in Sweden in 1998–99. More recently, information from Reitox national
focal points has indicated that tablets had been seized which were white in
appearance, had no logo and were approximately 8.5 to 8.8 mm x 3.4 to 3.7 mm,
weighing 247 to 249 mg (in France and Denmark, respectively).
As 2C-T-2 comes in powder or tablet form, the primary route of administration is
oral. However, insufflation (snorting) is also commonly mentioned in user reports. In a
survey of 43 self-reporting 2C-T-2 users, the following percentages of respondents
indicated their usual routes of administration: oral (83.7 %) and insufflation (16.3 %).
Unlike 2C-T-7, smoking and rectal or intravenous/intramuscular administration were
not mentioned. Original studies by Shulgin involved oral administration of 2C-T-2 in
doses of between 12 and 25 mg. This is compared to Pihkal ‘recommended’ doses of
80 to 150 mg for MDMA, 178 to 256 mg for mescaline (hydrochloride), 12 to 24
mg for 2C-B, 60 to 100 mg for 2C-T, 10 to 30 mg for 2C-T-7, 1 to 3 mg for DOB
and 3 to 10 mg for DOM. Respondents in a user survey mentioned oral doses of
between 5 and 40 mg (average 21 mg) and intranasal doses of between 2.5 and 
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35 mg (average 13 mg). Compared to the wide-ranging doses mentioned for 2C-T-7,
by inference this may indicate that there is less individual sensitivity to 2C-T-2.
Health risks
Individual health risks
Acute effects
No scientific evidence related to the action of 2C-T-2 on neurotransmitter systems has
been published to date, so discussion of the neuropharmacological aspects of 2C-T-2
at the risk assessment meeting was based on speculative comparison with partially
related compounds such as 2C-B (based on phenethylamine) and DOB (based on
amphetamine), both involving bromine as opposed to sulphur.
Studies involving a bromine-substituted analogue, 2C-B (4-bromo-2,5-
dimethoxyphenethylamine), have shown it to be a partial agonist for 5-HT2 (5-HT2A
and 5-HT2C) serotonergic receptors and 1-adrenergic receptors. At 10-6M, 2C-B also
acted as a competitive 5-HT antagonist, but, at higher concentrations (2.8 x 10-5M), it
acted as a non-competitive 5-HT antagonist. In addition, DOB (4-bromo-2,5-
dimethoxyamphetamine) was found to have a high affinity for 5-HT2 receptors,
whereas 2C-B was also found to have significant affinity for 5-HT1A, 5-HT1B and
5-HT1C receptors and thus was deemed to be less selective than its amphetamine-
based analogue, DOB.
As 2C-T-2 is phenethylamine based, it is possible it may have serotonergic receptor
affinity similar to 2C-B (i.e. binding to 5-HT2 and, to some degree, 5-HT1 receptors).
Researchers have already provided evidence of the involvement of 5-HT2 serotonergic
receptors (in particular 5-HT2A) in the action of hallucinogenic agents. It is
conceivable, therefore, that the apparent hallucinogenic effects of 2C-T-2 may be
related to similar receptor affinities. However, such conjecture is only based on limited
information on related compounds, and further specific studies of 2C-T-2 will be
required before definitive conclusions can be drawn.
Subjective evidence from user surveys indicates variable observations regarding
cardiovascular and thermoregulatory responses. However, the sample size of these
surveys was 10 times smaller than for 2C-T-7. Compared to 2C-T-7, where 31.9 % of
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users noted headaches (suggesting the possibility of raised blood pressure), only
9.3 % reported headaches with 2C-T-2. Although inconsistent observations regarding
its effect on body temperature were described for 2C-T-7, this information appears to
be associated with 2C-T-7, not 2C-T-2.
No metabolic studies have been performed for 2C-T-2. However, it is likely that its
metabolism proceeds via similar pathways to 2C-B, possibly with additional metabolic
reactions. Anecdotal evidence from user self-reports indicates an onset of action of
between one and two hours, with effects lasting up to 6 to 8 hours. However, these
data typically refer to oral ingestion, and users report more rapid onset and shorter
duration of effects following insufflation. This compares to 8 to 12 hours for orally
ingested LSD and 10 to 12 hours for mescaline, as described by Shulgin.
At present there are no animal or human data concerning general toxicity,
reproductive toxicity, neurotoxicity or the mutagenicity and carcinogenic potential of
2C-T-2. Only subjective evidence is available from user surveys involving observations
of apparent adverse effects and toxic symptoms. A study of self-reporting 2C-T-2
users indicated that side-effects of varying degrees were noted in the majority of
users, but none were prolonged or severe. The most common side-effect was nausea,
followed by muscle tension, vomiting, diarrhoea, tachycardia, dehydration,
headaches, hypertension and, to a lesser degree, stomach ache and confusion. It
should be noted that, overall, there were fewer instances of adverse effects with 2C-T-2
compared to 2C-T-7. However, the 2C-T-2 population surveyed only numbered 43,
far less than the 423 surveyed for 2C-T-7.
Unlike other phenethylamine derivatives (including 2C-B), 2C-T-2 is not usually
present in tablets containing other phenethylamines or stimulants, which reduces the
possibility of concomitant ingestion of other drugs. However, as the pharmacology of
2C-T-2 is largely unknown, it is difficult to predict with accuracy any potential drug
interaction or contraindication. Acute effects of monoamine reuptake inhibitors (SSRIs)
on the stimulatory effects of hallucinogens have been observed in one study, showing
an additivity of effects rather than a potentiation. Similar effects could possibly occur
with 2C-T-2. There have also been various reports of potential adverse interaction
with monoamine oxidase inhibitors (MAOIs) (Murple, 2001). However, specific studies
of such drugs in combination with 2C-T-2 have not been performed, so the potential
interactions described above have not been confirmed.
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Clinical effects
There have been no reported deaths or instances of non-fatal intoxication involving
2C-T-2. As it has not undergone any clinical or pre-clinical evaluation studies, the
majority of data on 2C-T-2 is based on self-reporting by users. In general, users
reported strong visual effects, emotional responses (similar to MDMA) and some
negative psychedelic mental effects such as anxiety, paranoia and panic attacks.
Adverse effects such as nausea, muscle tension and vomiting were also noted.
Dependence
No specific research has been performed to evaluate the dependence potential of 
2C-T-2 in animals or humans. Anecdotal user reports suggest that tolerance to the
effects of 2C-T-2 can occur in some instances. If tolerance does occur, it is possible
that there may also be cross-tolerance between other related psychedelic
phenethylamines such as 2C-T-7, 2C-B and mescaline. Although the specific
pharmacology of 2C-T-2 is unknown, speculative comparison with related compounds
suggests it is unlikely to produce physical dependence or addiction. However, without
any specific studies, definitive conclusions cannot be drawn.
Psychological effects
There are no published data on the specific psychological effects, acute or chronic, of
2C-T-2. Some of the 43 respondents providing self-reports for the survey mentioned
above reported experiencing feelings of wellbeing and mental clarity a day after
ingestion, but others described feeling mentally drained and emotionally unbalanced.
Public health risks
Availability and quality of 2C-T-2 on the market
2C-T-2 has been identified in six Member States: Denmark, Germany, France, the
Netherlands, Finland and Sweden.
Information based on early-warning databases suggests that 2C-T-2 is very rare.
However, it was found in the EU between 1998 and mid-2002 (France, August
2002). Denmark reported a case of international trafficking (2 038 tablets seized on
26 January 2001).
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From 1997, 2C-T-2 was sold in smartshops in the Netherlands. In 1998, ‘Conscious
dreams’ began to market 2C-T-2, whilst De Sjamaan Internet suppliers were
independently obtaining and selling 2C-T-2. In 1998, a ‘smart’ drugstore in Sweden
was also selling 2C-T-2. Smartshops stopped selling 2C-T-2 as a result of controls
introduced in April 1999 in the Netherlands and Sweden. In April 2000, 2C-T-2 was
available on the international market in a pure powder form from a handful of
chemical supply companies, though these companies explicitly forbade human use in
their customer agreements. An Internet search using the Google search engine in
March 2003 did not find online sales of 2C-T-2.
On the basis of limited information, it is possible to state that tablets typically contain
10 mg of 2C-T-2. In the Netherlands, white tablets containing 2C-T-2 were sold as
2C-T-7 in 1997. In France, white tablets containing 2C-T-2 were sold as ‘mescaline’
in August 2002. The fact that a significant amount of 2C-T-2 tablets with no logo has
been seized in Denmark could be a matter for serious concern, because of the risk of
confusion with MDMA among the wider population of ecstasy users.
According to Internet sources, in 1998 the estimated price of 2C-T-2 was between
EUR 3 and 4 per tablet.
Knowledge and perception of 2C-T-2 among users
Level of awareness about 2C-T-2 is generally negligible, except among small
subgroups of experimenters who may use 2C-T-7, mescaline, DOB or 2C-B for
particular effects. Due to the lack of research studies, the level of knowledge among
these particular consumer subgroups (as can be seen on the Internet) appears to be
more detailed than in the general scientific community. However, perceptions among
consumers about the contents of products sold as 2C-T-2 are usually based on the
information provided by suppliers and the beliefs of consumers. In the absence of
accurate and regulated chemical analysis, objective scientific knowledge remains
extremely limited. Major information sources are Internet sites and ‘dance floor
pharmacology’ (an informal network whereby information passes from friend to
friend). Despite warnings about the potential harm associated with using health
information from the Internet, a systematic search of peer-reviewed literature found
few reported cases of harm. This may be due to an actual low risk for harm
associated with the use of information available on the Internet, or to under-reporting
of such cases, or to bias.
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Prevalence and patterns of use
Scientific evidence of 2C-T-2 use within the EU is very limited. In the Netherlands,
targeted surveys conducted by the Amsterdam Antennae project in different settings
found lifetime prevalence of 2C-T-2 of around 2 %, compared to over 50 % for
ecstasy. An Internet survey obtained 43 valid responses from people who had taken
2C-T-2; however, their country of residence is unknown. According to the same
survey, use ranged from 1 to 20 times, with an average of 3.69 times; doses ranged
from 5 to 40 mg, with the average being 21 mg. The reported administration routes
were oral (84 %) and by insufflation (16 %). Participants in Internet surveys and
newsgroups report combined use with other drugs, but not as much as with 2C-T-7.
Population surveys of young adults in the EU show that a range of from 1 % in
Finland to 12 % in the United Kingdom have lifetime prevalence of using
hallucinogenic substances, most commonly ‘magic’ mushrooms. School surveys of 15-
to 16-year-olds in the EU show that 1 to 5 % of this age group have used LSD or
other hallucinogens, compared to 10 % in the USA (EMCDDA and ESPAD).
Characteristics and behaviour of users
An Internet survey of 43 respondents shows that 91 % of respondents were male and
the age of those who had tried 2C-T-2 ranged from 16 to 47 years.
2C-T-2 users may belong to a small group of people with a pseudo-scientific interest
in experimenting with hallucinogenic substances, often referred to as ‘psychonauts’.
There appears to be a trend among a small but significant minority towards
broadening their repertoire of drug experiences, involving a wider range of drugs
and combinations. Special concerns relate to the lack of knowledge about the drug
contents and the specific harmful effects of 2C-T-2, either alone or combined with
other drugs.
Indicators of health consequences
Information on the health consequences of 2C-T-2 use is limited. The section on
‘Clinical effects’ describes information gathered from what appears to be a very small
population of users. There is no information available on the long-term consequences
of 2C-T-2 use.
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Context of use
There is no scientific evidence about risk factors linked to the circumstances and
consumption practices associated with 2C-T-2 use.
Social risks
Sociological aspects
Young people outside of the ecstasy-using population are relatively unlikely to come
into contact with 2C-T-2 under present conditions. However, the seizure in Denmark in
2001 of 2 038 tablets with no logo indicates that such a possibility cannot be
excluded.
As with all illicit drug use, lack of scientific and objective information contributes
towards increased risk. Firstly, inaccurate media coverage and overestimation of
prevalence may promote diffusion by encouraging young people to try it. Secondly,
official dissemination of inaccurate information is counterproductive, as it can
undermine credibility.
A few more experimental drug users appear to be motivated by a desire to
experience a wide range of sensations. The number is not known, but they are not an
insignificant group. However, the erratic and highly dose-sensitive nature of 2C-T-2
and negative adverse effects such as nausea, muscle tension and vomiting suggest
that there may be little likelihood that 2C-T-2 will grow in popularity or become
widely used.
Social consequences
There is currently no scientific evidence of negative social consequences. However,
2C-T-2 carries potential risks common to other hallucinogenic substances that are
already controlled.
Consequences for the social behaviour of the user
There is no specific evidence to link the use of 2C-T-2 to disorderly conduct,
acquisitive crime or violence. However, the long duration of action with 2C-T-2 may
have implications for driving a vehicle and using machinery.
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Other social consequences
There is no indication that 2C-T-2 is particularly associated with any major value
conflicts or has any important implications for social institutions beyond those
described for similar compounds, such as 2C-B or DOB.
Criminological aspects
The law enforcement agencies of all 15 Member States reported to Europol that there
is no information available to suggest that there is large-scale production, distribution
and/or trafficking in 2C-T-2 or that organised crime has a role in these activities.
Belgium and Italy reported that the main reason for the lack of information is that the
substance is not controlled in those countries and, therefore, no records are kept by
the law enforcement agencies.
Germany reported that a limited quantity of 2C-T-2 was produced in 1999. This
related to one case only, involving a small ‘kitchen-type’ laboratory in Brannenburg,
Bavaria.
Five Member States reported seizures of 2C-T-2. These were small, both in terms of
numbers and quantities seized. One of these, Denmark, reported a case of
international trafficking involving a seizure of 2C-T-2 in November 2000. This
resulted from a criminal investigation which had revealed that a suspect was to
receive drugs by mail from the Netherlands. The package, which was intercepted,
contained 2 038 tablets of 2C-T-2 in two cans carrying the words ‘Think fast, Hedoné
1 000 tablets’. Finland reported a seizure of four tablets of 2C-T-2 in 2001. France
reported a seizure of one tablet of 2C-T-2 in 1998. Germany reported a seizure, in
1999, of 5.3 gm of 2C-T-2 from the laboratory in Brannenburg, and, in Sweden, six
seizures of 2C-T-2 occurred in 1998, three in 1999, two in 2000 and one in 2001. In
all the Swedish cases, the amounts seized were small and occurred at street level. In
the Netherlands, DIMS reported two cases of 2C-T-2: one in a tablet in April 2000
and one in powder form in June 2001.
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Prohibition
Legal status
An analysis of the legal status of 2C-T-2 in the 15 Member States shows that the drug
is controlled in five Member States. In Germany, 2C-T-2 was placed under Schedule I
on 7 October 1998 (listed as 4-Ethylsulfanyl-2,5-dimethoxyphenethylazan). In
Sweden, 2C-T-2 was placed under ‘emergency scheduling’ on 1 April 1999. In the
United Kingdom, 2C-T-2 is a Class A drug. In Ireland, 2C-T-2 comes under Schedule I
and it is a controlled drug in Greece.
2C-T-2 is not controlled in the USA.
Possible consequences of prohibition
The meeting noted that 2C-T-2 is already controlled in five Member States. It was also
noted that, structurally, 2C-T-2 is a potent hallucinogen comparable to substances
already classified under Schedules I or II of the 1971 United Nations Convention on
Psychotropic Substances. The meeting also noted that 2C-T-2 has no medical or
industrial use.
Arising from the above, it was felt that there is no real alternative to prohibition as a
control measure. It was widely agreed that this would enhance the capacity for
detection and monitoring of the drug on the market and limit the potential for
expansion in the supply and use of 2C-T-2. Another supporting argument was that
exempting 2C-T-2 from legal control would send an inaccurate message about the
comparative safety of the substance. Increased availability of information about the
drug would also stimulate the gathering and dissemination of analytical information
for public health purposes.
The meeting feared that prohibition could engender stigmatisation of the small self-
limiting groups of 2C-T-2 users. It was also felt that the lack of scientific evidence
makes it very difficult to determine the possible consequences of legal controls.
There was a consensus of opinion that control measures should not prevent the
dissemination of accurate information about 2C-T-2 to users and to relevant
professionals for preventive and harm reduction measures. Marginalisation of 2C-T-2
users should be avoided.
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Conclusions
The Scientific Committee of the EMCDDA, extended with experts from the Member
States and representatives of the Commission, Europol and the EMEA, has considered
the health and social risks as well as the possible consequences of prohibition of 
2C-T-2 and, in accordance with Article 4 of the joint action, submits the following
conclusions.
• 2C-T-2 has the structural characteristics of phenethylamines, which are associated
with stimulant and hallucinogenic activity. This would appear to make it comparable
to substances already classified in the schedules of the 1971 United Nations
Convention on Psychotropic Substances, such as 2C-B (listed in Schedule II as 4-
bromo-2,5-dimethoxyphenethylamine).
Specific scientific risk assessment of 2C-T-2 is extremely difficult due to the lack of
peer-reviewed scientific data. However, information based on analogy with 2C-B and
DOB and evidence classified to evidence level IV (5) indicate the following.
• 2C-T-2 is a synthetic drug that was first synthesised in 1981 by Shulgin.
• Seized/available material includes powder and tablets (white, no logo).
• 2C-T-2 has no current medical or industrial use.
• It is a potential 5-HT2C, 5-HT2A and 5-HT1 serotonergic and 1-adrenergic receptor
agonist.
• Users report hallucinogenic/visual effects similar to 2C-B, LSD and mescaline and
feelings of empathy similar to MDMA. There may be side-effects such as nausea,
muscle tension, vomiting, anxiety and some confusion/disorientation; however, no
scientific data are available.
• Self-reporting users have only mentioned oral ingestion and insufflation (snorting) of
2C-T-2.
• Due to the lack of specific scientific evidence, acute or chronic toxicity has not been
confirmed in humans, but toxic effects cannot be excluded.
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• There have been no reported cases of fatal or non-fatal intoxication.
• There is currently no scientific evidence of negative social consequences. However,
2C-T-2 carries risks common to other hallucinogenic substances that are already
controlled.
• There has been one reported case of international trafficking of 2C-T-2 in
November 2000, involving two EU Member States.
• 2C-T-2 has been identified in six Member States and it is controlled in five.
Recommendations
• The meeting was strongly of the opinion that, due to its hallucinogenic/stimulant
properties and potential serious risk for health, 2C-T-2 should be a controlled
substance. However, there were some experts who felt that there was insufficient
scientific evidence to make such a recommendation.
• The meeting also recommended that any decision to place 2C-T-2 under legal
control should not inhibit the gathering of information about drugs on the market
and the dissemination of accurate information on 2C-T-2 to users and relevant
professionals.
• The major chemical precursor of 2C-T-2, namely 2,5-dimethoxythiophenol, is
commercially available. Should the substance be controlled, the meeting
recommended that the Drug Precursors Committee (set up under Article 10 of
Regulation (EEC) No 3677/90 and Directive 92/109/EEC) closely examine the
situation of this precursor chemical, which is involved in the synthesis of 2C-T-2 and
is not yet subject to any surveillance measures.
• The meeting reiterated its earlier recommendation that, when a new synthetic drug
is notified for risk assessment, arrangements be made for the provision of standard
reference materials and associated analytical data to forensic and toxicology
laboratories within the European Union. The meeting further recommended that 
2C-T-2 be included within the UNDCP proficiency-testing programme.
Lisbon, 31 March 2003


Chapter 1
Report on the risk assessment of 2C-T-7 in the
framework of the joint action on new synthetic
drugs
On 12 December 2002, the horizontal working party on drugs of the Council of the
European Union decided that risk assessment of four new synthetic drugs, 2C-T-2, 
2C-T-7, 2C-I and TMA-2, should be initiated. On 20 December 2002, in accordance
with practice under the 1997 joint action, the Danish Presidency formally notified the
EMCDDA of the decision of the HWPD to submit 2C-T-2, 2C-T-7, 2C-I and TMA-2 for
risk assessment under Article 4 of the joint action on new synthetic drugs of 16 June
1997.
A meeting of the Scientific Committee of the EMCDDA, extended with experts
nominated by the Member States and representatives of the European Commission,
Europol and the EMEA, was held on 31 March 2003 to assess the health and social
risks of 2C-T-7, as well as the possible consequences of prohibition.
The meeting considered the following documents.
i. Review of the pharmacotoxicological data for the risk assessment of 2C-T-7;
report to the EMCDDA
ii. Public health risks: epidemiological evidence; EMCDDA
iii. Sociological/criminological evidence; EMCDDA
iv. Europol contribution to the risk assessment on 2C-T-7
In conjunction with further information and comments from the expert participants,
these documents formed the basis of the risk assessment which is reported below.
Chemical description
2C-T-7 is 2,5-dimethoxy-4-(n)-propylthiophenethylamine. Other chemical names are
rearrangements of the different elements of this name, such as 4-propylthio-2,5-
dimethoxy-phenethylamine (or PT-DM-PEA). The synthesis protocol described in Pihkal
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by Shulgin and Shulgin (1991), who are thought to have first synthesised 2C-T-7 in
1986, is based on the initial use of 1,4-dimethoxybenzene to eventually produce a
preliminary precursor, 2,5-dimethoxythiophenol. Described by Shulgin as a ‘valuable
precursor to all members of the 2C-T family’, the latter compound is now
commercially available. The abovementioned method requires specialist equipment
and an appropriate environment. The exact method of synthesis used by clandestine
laboratories is not known.
2C-T-7 exhibits a slow/weak ‘salmon orange’ (pink, orange-red) colour using the
Marquis reagent assay.
At present, 2C-T-7 has no medical or industrial use.
Pharmaceutical description
2C-T-7 is typically available in powder or tablet form, but may also be found in
capsules or liquid form. It appears to have various ‘street names’, including ‘T-seven’,
‘Beautiful’, ‘Lucky seven’, ‘Seven-up’, ‘Seventh heaven’, ‘Red raspberry’, ‘Tweety bird
mescaline’ and ‘Tripstacy’. 2C-T-7 used to be commercially available in the EU
(1999–2001) as ‘Blue mystic’. It was available from Dutch smartshops as a blue tablet
with a ‘Yin-yang’ logo.
As 2C-T-7 comes in powder or tablet form, the primary route of administration is
oral. However, insufflation (snorting) is also commonly mentioned in user reports.
Some less common routes of administration include smoking, rectal administration
and intravenous or intramuscular administration. Original studies by Shulgin involved
oral administration of 2C-T-7 in doses of between 20 and 30 mg, but the study
indicated that around 10 mg may be sufficient for some users. The very few self-
reports from intravenous/intramuscular users mentioned doses of between 1 and 
3 mg.
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Health risks
Individual health risks
Acute effects
No evidence related to the action of 2C-T-7 on neurotransmitter systems has, as yet,
been published in peer-reviewed scientific journals, so discussion of the
neuropharmacological aspects of 2C-T-7 at the risk assessment meeting was based on
speculative comparison with partially related compounds such as 2C-B (which is
based on phenethylamine) and DOB (which is based on amphetamine), both
involving bromine as opposed to sulphur. 2C-B and DOB are already classified in
Schedules II and I, respectively, of the 1971 UN Convention.
Studies involving a bromine-substituted analogue, 2C-B (4-bromo-2,5-
dimethoxyphenethylamine), have shown it to be a partial agonist for 5-HT2 (5-HT2A
and 5-HT2C) serotonergic receptors and 1-adrenergic receptors. At 10-6M, 2C-B also
acted as a competitive 5-HT antagonist, but, at higher concentrations (2.8 x 10-5M), it
acted as a non-competitive 5-HT antagonist. In addition, DOB (4-bromo-2,5-
dimethoxyamphetamine) was found to have a high affinity for 5-HT2 receptors,
whereas 2C-B was also found to have significant affinity for 5-HT1A, 5-HT1B and
5-HT1C receptors and thus was deemed to be less selective than its amphetamine-
based analogue, DOB.
As 2C-T-7 is phenethylamine based, it is possible that it may have serotonergic
receptor affinity similar to 2C-B (i.e. binding to 5-HT2 and, to some degree, 5-HT1
receptors). Researchers have already provided evidence of the involvement of 5-HT2
serotonergic receptors (in particular 5-HT2A) in the action of hallucinogenic agents. It
is conceivable, therefore, that the apparent hallucinogenic effects of 2C-T-7 may be
related to similar receptor affinities. However, such conjecture is only based on limited
information on related compounds and further specific studies of 2C-T-7 will be
required before definitive conclusions can be drawn.
Subjective evidence from user surveys indicates variable observations regarding
cardiovascular and thermoregulatory responses. The tachycardia and/or headaches
reported by a number of users were thought to indicate the possibility of increased
blood pressure. However, the value of such reports is seriously limited by the lack of
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medical confirmation and the inconsistency of observations regarding effects on body
temperature.
No metabolic studies have been conducted for 2C-T-7. However, it is likely that its
metabolism may proceed via similar pathways as 2C-B, possibly with additional
metabolic reactions. Anecdotal evidence indicates an onset of action of between one
and two and a half hours, particularly if the substance is taken on an empty stomach,
with effects lasting up to 15 hours. However, these data typically refer to oral
ingestion and users report more rapid onset and shorter duration of effects following
insufflation.
At present, there are no animal or human data concerning general toxicity,
reproductive toxicity, neurotoxicity or the mutagenicity and carcinogenic potential of
2C-T-7. Only subjective evidence is available from user surveys involving observations
of apparent adverse effects and toxic symptoms. According to user self-reports, 
2C-T-7 use involving intranasal administration appeared to result in a greater number
of references to adverse effects than with oral administration. The most common 
side-effect was nausea, followed by headaches, vomiting, tachycardia, dehydration,
diarrhoea, hypertension and, to a lesser degree, gastrointestinal effects, confusion or
delirium (at high doses), dizziness and muscle spasms.
Unlike other phenethylamine derivatives (including 2C-B), 2C-T-7 tablets do not
usually contain other phenethylamines or stimulants, thus reducing the possibility of
concomitant ingestion of other drugs in such illicit preparations. However, as the
pharmacology of 2C-T-7 is largely unknown, it is difficult to predict with accuracy any
potential drug interaction or contraindication. Acute effects of monoamine reuptake
inhibitors (SSRIs) on the stimulatory effects of hallucinogens have been observed in
one study, showing an additivity of effects rather than a potentiation. Similar effects
could possibly occur with 2C-T-7. Potential adverse interaction with monoamine
oxidase inhibitors (MAOIs) has been mentioned in various user reports and by
Shulgin. However, specific studies of such drugs in combination with 2C-T-7 have not
been conducted, so the potential interactions described above have not been
confirmed.
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Clinical effects
2C-T-7 has been implicated in three deaths in the USA. Of these, the presence of 
2C-T-7 was confirmed in one case following specific toxicological analysis.
Preliminary information on this case suggests that only 2C-T-7 was taken: 35 mg
intranasally (snorting).
No deaths have been linked to 2C-T-7 within Europe. However, the lack of reference
material may compromise the analysis of post-mortem cases.
There have been no confirmed cases of non-fatal intoxication. 2C-T-7 is not usually
detected during routine toxicological analysis. As for post-mortem toxicological
investigations, the lack of reference material may compromise clinical toxicological
analysis in hospital settings. Anecdotal cases included in the user survey responses
published on the Internet occurred in the USA, Mexico, Finland and the Netherlands.
Further data are required before the involvement of 2C-T-7 can be established and
accurate mortality and morbidity figures produced.
Dependence
There have been no systematic studies of the tolerance or dependence potential of 
2C-T-7. If tolerance does occur, it is possible that cross-tolerance may occur between
other related psychedelic phenethylamines such as 2C-T-2, 2C-B and mescaline.
Although the specific pharmacology of 2C-T-7 is unknown, speculative comparison
with related compounds suggests it is unlikely to produce physical dependence or
addiction. However, without any specific studies, definitive conclusions cannot be
drawn.
Psychological effects
There are no published data on the specific psychological effects, acute or chronic, of
2C-T-7. The available data are essentially based on self-reporting by users. Users
describe the psychological effects of 2C-T-7 as similar to other hallucinogens such as
2C-B, LSD and mescaline. A large number of specific effects are reported on the
Internet, but the most common are: strong visual effects, emotional responses (similar
to MDMA), some negative psychedelic mental effects (anxiety, paranoia, panic
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attacks), delirium (at high doses), increased suppleness and enhancement of the
senses. The effects are typically described as being intense and may also include
severe disorientation/disassociation at high doses, particularly following insufflation.
Reported after-effects include euphoria or, conversely, ‘mental sluggishness’, including
impaired memory recall, mild confusion/disorientation and difficulty in concentrating.
Public health risks
Availability and quality of the product on the market
Between 1998 and 2001, 2C-T-7 has been identified in six Member States: Germany,
France, the Netherlands, Finland, Sweden and the United Kingdom. Four of these
reported small seizures were at street level. In early 2000, 2C-T-7 began to be sold in
smartshops in the Netherlands by De Sjamaan Internet suppliers under the brand
name of ‘Blue mystic’. This took the form of blue tablets with a ‘Yin-yang’ logo.
Distribution stopped in May 2001. In 2000, a seizure of four ‘Blue mystic’ 2C-T-7
tablets was recorded by DIMS and a small amount of 2C-B was also found. In
January 2000, 2C-T-7 was available on the international market in pure powder form
from a handful of chemical supply companies, though these companies explicitly
forbade human use in their customer agreements. From summer 2000 onwards,
discussion of 2C-T-7 on the Internet between groups of ‘experimental’ users has
significantly grown. However, the availability of this drug at street level seems to be
currently very low, especially in Europe. In 2001, DIMS recorded finding a small
amount of 2C-T-7 in powder form. According to a project report by Amsterdam
Antennae, 2C-T-7 has not been available in Amsterdam for nearly two years. An
Internet Google search in March 2003 did not find online sales of 2C-T-7.
2C-T-7 was also detected in 2000 in Canada (with the street name ‘Red raspberry’)
and has been reported sporadically in the United States (with various street names),
where three deaths apparently involving this compound in high doses have been
reported.
On the basis of limited information, tablets/capsules typically contain 10 mg of the
active compound (one sample of 20 mg was seized in Germany). According to
Internet sources, in 2000 the estimated price of 2C-T-7 ranged between EUR 2 and 5
per tablet.
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Knowledge and perception of 2C-T-7 among users
The level of awareness about 2C-T-7 amongst drug consumers is generally negligible,
except among small subgroups of experimenters who may use mescaline, DOB or 
2C-B for particular effects. Due to the lack of research studies, the level of knowledge
among these particular consumer subgroups (as can be seen on the Internet) appears
to be more detailed than in the general scientific community. However, perceptions
among consumers about the contents of products sold as 2C-T-7 are usually based on
the information provided by suppliers and the beliefs of consumers. In the absence of
accurate and regulated chemical analysis, objective scientific knowledge remains
extremely limited. Major information sources are Internet sites and ‘dance floor
pharmacology’ (an informal network whereby information passes from friend to
friend). Despite warnings about the potential harm associated with using health
information from the Internet, a systematic search of peer-reviewed literature found
few reported cases of harm. This may be due to an actual low risk for harm
associated with the use of information available on the Internet, or to under-reporting
of such cases, or to bias.
In 1997, white tablets containing 2C-T-2 were sold as 2C-T-7 in Dutch smartshops. In
2000, a small amount of 2C-B was found in one of the four tablets of 2C-T-7
recorded by DIMS in the Netherlands. Since 2C-T-7 has been available in pure
powder form, a small number of severe panic reactions have been reported on
Internet forums. This appears to have been due to the drug ketamine being confused
with 2C-T-7 by users snorting ketamine-sized doses of 2C-T-7. Moreover, participants
in Internet surveys and newsgroups have reported an extensive range of combinations
with other drugs.
Prevalence and patterns of use
Scientific evidence of 2C-T-7 use within the EU is very limited. In the Netherlands,
targeted surveys conducted by the Amsterdam Antennae project in different settings
found lifetime prevalence of 2C-T-7 use to be less than 1 %, compared to over 50 %
for ecstasy. In the United Kingdom, a dance music magazine survey of nearly 500
respondents in 2002 found that none of them had ever tried 2C-T-7. An Internet
survey of 2C-T-7 users obtained 423 valid responses from people who had taken 
2C-T-7. However, the countries of residence of these respondents are unknown,
although it is probable that many were from the USA. In this Internet survey from a
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non-representative sample of the general population, prevalence of use ranged from
1 to 200 times, with an average of 4.78 times. Doses ranged from 1 to 125 mg, with
the average being 27 mg. The administration routes for 2C-T-7 were usually oral
(69 %) or intranasal (28 %). Very low levels of use by smoking, rectal insertion and
injecting were also reported.
Two major factors that affect trends are availability and reliability of effects. 2C-T-7 is
less available now than in 1999–2001 and people looking for new experiences may
have moved on to other products. The author of the Internet survey cited above
suggests that the effects of 2C-T-7 are erratic and highly dose-sensitive, making it
unlikely to become very popular.
Population surveys in the EU show that a range of 1 % of young adults in Finland to
12 % in the United Kingdom have had ‘lifetime prevalence’ of using hallucinogenic
substances, most commonly ‘magic’ mushrooms. School surveys of 15- to 16-year-
olds in the EU show that 1 to 5 % of this age group have used LSD or other
hallucinogens, compared to 10 % in the USA (EMCDDA and ESPAD).
Characteristics and behaviour of users
An Internet survey of 423 respondents shows that 89.4 % of respondents were male
and 9.9 % were female (0.7 % did not specify), with an age range of 14 to 64
(average 27 years old).
2C-T-7 users may belong to a small group of people with a pseudo-scientific interest
in experimenting with hallucinogenic substances, often referred to as ‘psychonauts’.
There appears to be a trend among a small but significant minority towards
broadening their repertoire of drug experiences, involving a wider range of drugs
and combinations of drugs.
Indicators of health consequences
Information on the health consequences in the population is limited to an apparently
very small population of users. There is no information available on the long-term
consequences of 2C-T-7 use.
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Context of use
There is no scientific evidence about risk factors linked to the circumstances and
consumption practices associated with 2C-T-7 use. However, anecdotal user reports
mention an apparent increased prevalence and duration of side-effects following
insufflation, indicating a potential harm/toxicity risk. Two of the three fatalities
implicating 2C-T-7 involved this route of administration.
Social risks
Sociological aspects
Young people outside of the ecstasy-using population are relatively unlikely to come
into contact with 2C-T-7 under present conditions.
As with all illicit drug use, lack of scientific and objective information contributes
towards increased risk. Firstly, inaccurate media coverage and overestimates of use
may promote diffusion by encouraging young people to try it. Secondly, official
dissemination of inaccurate information is counterproductive, as it can undermine
credibility.
A few more experimental drug users appear to be motivated by a desire to
experience a wide range of sensations. The number is not known, but they are not an
insignificant group. However, the erratic and highly dose-sensitive nature of 2C-T-7
and negative adverse effects such as nausea, headaches, intoxication and instances
of death described on the Internet suggest that there may be little likelihood that 
2C-T-7 will grow in popularity or become widely used.
Social consequences
There is currently no scientific evidence of negative social consequences. However,
2C-T-7 carries potential risks common to other hallucinogenic substances.
Consequences for the social behaviour of the user
There is no specific evidence to link the use of 2C-T-7 to disorderly conduct,
acquisitive crime or violence. However, the long duration of its action may have
implications for driving and using machinery.
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Other social consequences
There is no indication that 2C-T-7 is particularly associated with any major value
conflicts or has any important implications for social institutions beyond those
described for similar compounds, such as 2C-B or DOB.
Criminological aspects
Between 1998 and 2001, 2C-T-7 was identified in Germany, France, the
Netherlands, Finland, Sweden and the United Kingdom. The law enforcement
agencies of all 15 Member States reported to Europol that there is no information
available that would suggest large-scale production, distribution and/or trafficking of
2C-T-7 or that organised crime has a role in these activities. Belgium and Italy
reported that the main reason for the lack of information is that the substance is not
controlled in those countries and, therefore, no records are kept by the law
enforcement agencies.
Germany reported that a limited quantity of 2C-T-7 was produced in 1999. This
related to one case only, involving a small ‘kitchen-type’ laboratory in Brannenburg,
Bavaria.
Four Member States reported seizures of 2C-T-7, but these were small, both in terms
of numbers and quantities seized. Finland reported a seizure of 0.06 gm of 2C-T-7 in
2001. France reported a seizure of three tablets of 2C-T-7 in 2001. Germany
reported a seizure of 7.7 gm of 2C-T-7 in 1999 from the laboratory in Brannenburg
and another seizure in Berlin, between 1996 and 1998 (no further details are
available). In Sweden, one seizure of 2C-T-7 occurred in 1998, one in 1999, one in
2000 and one in 2001. In all the Swedish cases, the amounts seized were small and
occurred at street level.
In the United Kingdom, the Reitox national focal point reported to the EMCDDA on
the discovery of three tablets of 2C-T-7 in an amnesty bin in a London club in 2000.
In the Netherlands, 2C-T-7 was distributed in smartshops between 1999 and 2000.
The total amount of 2C-T-7 seized in the Member States is very small when compared
to ecstasy seizures in the European Union (over 15 million tablets annually in recent
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years). Member States’ law enforcement agencies did not provide data on violence in
connection with the production, distribution and trafficking of 2C-T-7.
Possible consequences of prohibition
Legal status
An analysis of the legal status of 2C-T-7 in the 15 Member States shows that the drug
is controlled in four. In Germany, 2C-T-7 was placed under control on 20 January
1998. In Sweden, it is controlled under the emergency list. In the United Kingdom, it
is a Class A drug and it is also a controlled drug in Greece.
In the USA, in September 2002, the DEA issued a final order to place 2C-T-7
temporarily under Schedule I. This temporary scheduling will last for up to 18 months
or until the drug is permanently scheduled. 2C-T-7 is also controlled in Canada.
Prohibition
The meeting acknowledged that 2C-T-7 is already controlled in four Member States. It
noted that, structurally, 2C-T-7 is a potent hallucinogen comparable to substances
already classified under Schedules I or II of the 1971 United Nations Convention on
Psychotropic Substances. It was also noted that 2C-T-7 has no medical or industrial
use.
Arising from the above, it was felt that there is no real alternative to prohibition as a
control measure. It was widely agreed that such measures would enhance the
capacity for detection and monitoring of the drug on the market and limit the
potential for expansion of the supply and use of 2C-T-7. Another supporting argument
was that exempting 2C-T-7 from legal control would send an inaccurate message
about the comparative safety of the substance. Increased availability of information
about the drug would also stimulate the gathering and dissemination of analytical
information for public health purposes.
The meeting feared that prohibition could engender stigmatisation of the small self-
limiting groups of 2C-T-7 users. It was also felt that the lack of scientific evidence makes
it very difficult to determine the possible consequences of legal controls on 2C-T-7.
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There was a consensus of opinion that control measures should not prevent the
dissemination of accurate information on 2C-T-7 to users and to relevant professionals
for preventive and harm reduction measures. Marginalisation of 2C-T-7 users should
be avoided.
Conclusions
The Scientific Committee of the EMCDDA, extended with experts from the Member
States and representatives of the Commission, Europol and the EMEA, has considered
the health and social risks as well as the possible consequences of prohibition of 
2C-T-7 and, in accordance with Article 4 of the joint action, submits the following
conclusions.
• 2C-T-7 has the structural characteristics of phenethylamines, which are associated
with stimulant and hallucinogenic activity. This would appear to make it comparable
to substances already classified in the schedules of the 1971 United Nations
Convention on Psychotropic Substances, such as 2C-B (listed in Schedule II as 4-
bromo-2,5-dimethoxyphenethylamine).
Specific scientific risk assessment of 2C-T-7 is extremely difficult, due to the lack of
peer-reviewed scientific data. However, information based on analogy with 2C-B and
DOB and evidence classified to evidence level IV (6) indicate the following.
• 2C-T-7 is a synthetic drug that was first synthesised in 1986 by Shulgin.
• Seized/available material includes powder, tablets (blue, ‘Yin-yang’ logo), capsules
or liquid preparations.
• 2C-T-7 has no current medical or industrial use.
• It is a potential 5-HT2C, 5-HT2A and 5-HT1 serotonergic and 1-adrenergic receptor
agonist.
• Users report hallucinogenic/visual effects similar to 2C-B, LSD and mescaline and
emotional responses similar to MDMA. There may be effects such as nausea,
(6) Refers to the classification of information sources in Guidelines for risk assessment of new synthetic drugs, adopted by
the EMCDDA’s Scientific Committee.
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headaches, vomiting, anxiety, confusion/disorientation, agitation, aggression and
violent behaviour; however, no scientific data are available.
• Both oral ingestion and insufflation (snorting) of 2C-T-7 have been reported.
However, self-reporting users have also mentioned rectal administration and
injecting.
• Due to the lack of specific scientific evidence, acute or chronic toxicity has not been
confirmed in humans, but toxic effects cannot be excluded.
• There has been one death in which the involvement of 2C-T-7 has been confirmed
in the USA; no fatalities have been reported in Europe. There have been no
confirmed reports of non-fatal intoxication.
• There is currently no scientific evidence of negative social consequences. However,
2C-T-7 carries risks common to other hallucinogenic substances that are already
under control.
• There is no evidence to suggest that there is large-scale production and trafficking
of 2C-T-7 or any involvement of organised crime.
• 2C-T-7 has been identified in six Member States and it is controlled in four.
Recommendations
• The meeting was strongly of the opinion that, due to its hallucinogenic/stimulant
properties and potential serious risk for health, 2C-T-7 should be a controlled
substance. However, there were some experts who felt that there was insufficient
scientific evidence to make such a recommendation.
• The meeting also recommended that any decision to place 2C-T-7 under control
should not inhibit the gathering of information about drugs on the market and the
dissemination of accurate information on 2C-T-7 to users and relevant professionals.
• The major chemical precursor of 2C-T-7, namely 2,5-dimethoxythiophenol, is
commercially available. Should the substance be controlled, the meeting
recommended that the Drug Precursors Committee (set up under Article 10 of
Regulation (EEC) No 3677/90 and Directive 92/109/EEC) closely examine the
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situation of this precursor chemical, which is involved in the synthesis of 2C-T-7 and
is not yet subject to any surveillance measures.
• The meeting reiterated its earlier recommendation that, when a new synthetic drug
is notified for risk assessment, arrangements be made for the provision of standard
reference materials and associated analytical data to forensic and toxicology
laboratories within the European Union. The meeting further recommended that 2C-
T-7 be included within the UNDCP proficiency-testing programme.
Lisbon, 31 March 2003
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Europol–EMCDDA progress report on 2C-I, 
2C-T-2 and 2C-T-7
Joint EMCDDA–Europol progress report on 2C-I, 2C-T-2 and 2C-T-7 to
the horizontal working party on drugs of the Council of the European
Union in the framework of the joint action on new synthetic drugs
1. Since the adoption of the joint action on new synthetic drugs in June 1997 and
the setting-up of the early warning system, a number of synthetic substances
have been detected and monitored.
2. Depending on different variables, such as the gravity of the consequences of
using a substance, the nature of the evidence, the frequency of its detection and
the scale of its presence on the market (notifications and seizures), the EMCDDA
and Europol:
(a) have produced joint reports for some of these substances (when the initial
estimation of risks has required it); and
(b) have continued to collect information on the others (those with less evident
risks), in order to build up a complete picture.
3. On the basis of the EMCDDA–Europol joint reports, the EMCDDA’s enlarged
Scientific Committee was requested to carry out risk assessments on selected
substances. Thus, risk assessment reports have been produced for the following
substances: MBDB, 4-MTA, GHB, ketamine and PMMA.
4. Following the normal risk assessment exercises and procedures, decisions were
taken to put some of these substances (4-MTA, PMMA) under control and to
continue to monitor the others (MBDB, GHB, ketamine).
5. In the meantime, the EMCDDA and Europol have obtained more information on
a number of other substances. These are: 2C-T-2, 2C-T-7, 2C-I, TMA-2, BZP,
TFMPP, PMEA, DOC, 5-MeO-DMT, 5-MeO-DIPT, DXM, DPT, A-MT and ALEPH-7.
6. This report presents the current information on 2C-I, 2C-T-2 and 2C-T-7.
7. The horizontal working party on drugs is requested to take note of this
information and to give instructions if the substance should undergo a risk
assessment.
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2C-I
Chemical and physical description
Chemical name: 2,5-dimethoxy-4-iodo-phenethylamine
Chemical structure:
2C-I                     2C-B
Molecular formula: C10H14INO2
Synonyms: 4-Iodo-2,5-dimethoxy-phenethylamine
(2,5-dimethoxy-4-iodophenyl)-2-aminoethane
4-Iod-2,5-dimethoxyphenethylazan (Germany)
Street name: ‘2C-I’ (seized tablets often have an ‘i’ logo)
Pharmaceutical form: tablet or powder
Route of administration, dose and duration
Route of administration: oral
Common dose range: 10 to 20 mg
Duration: 6 to 10 hours
Effects
2C-I is frequently compared to the controlled drug 2C-B (UN Schedule II), because of
the analogous chemical structures and subjective effects of the two drugs. With regard
to the latter, the entactogen (producing feelings of empathy) and energetic properties
of the two drugs are described by Shulgin as quite similar.
Health risks
The delayed onset of action (up to 90 minutes) of 2C-I could potentially lead users to
take too much of the drug if they become impatient (topping up before the effects hit)
and provoke adverse effects.
CH3O NH2
OCH3I
CH3O NH2
OCH3 *
Br  
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There have been no reported fatalities in the EU.
Legal status
2C-I is a ring-substituted phenethylamine, which is currently not listed under any of
the schedules of the 1971 UN Convention on Psychotropic Substances.
In Germany, 2C-I was put under permanent control on 19 June 2001. The substance
was already under control on a temporary basis from 1999. The arguments for
placing these kinds of drugs under permanent control can be found in the legal text
‘Fünfzehnte Betäubungsmittelrechts-Änderungsverordnung-15. BtMÄndV’ (19 June
2001). The substances covered are: (i) those that are used as ‘ecstasy’ drugs; and (ii)
those that are produced by illegal laboratories, which modify the chemical structure of
illegal drugs in order that they should not come under the law (‘designer drugs’).
In the United Kingdom, 2C-I comes within the definition of a controlled substance by
virtue of a generic description as set out in paragraph (i)(c) of the Misuse of Drugs
Act, 1977 (Controlled Drugs) (Declaration) Order, 1987.
In Denmark, 2C-I has been controlled since May 2002 (’Bekendtgørelse nr. 305 af
16. maj 2002 om ændring af bekendtgørelse om euforiserende stoffer’).
2C-I is not controlled in the USA.
Reports to the EMCDDA (5)
(A = reporting form; B = other)
Denmark (A): notification on 14 May 2002 of a seizure (in May 2002)
of one white pill containing 120 mg 2C-I and bearing an
‘i’ logo and of 2 ml in liquid form.
(8) Since the finalisation of this report, more information about 2C-I seizures in the EU has been accumulated: in the first
half of 2003 there were seven 2C-I seizures in the United Kingdom, two in Finland and six in Sweden. All the seizures
in the United Kingdom and one of those in Sweden were in tablet form with an ‘i’ logo; one of the seizures in Finland
was of tablets but no information is available about the logo. The remaining seizures in Sweden and one of the Finnish
seizures were in the form of a white powder. In October 2003, the EMCDDA received an official notification (A) of the
first identification of 2C-I in France, where six tablets were seized in Marseille. Furthermore, 2C-H (a compound that is
non-active in man), which is a precursor to 2C-I, 2C-C and 2C-B, was seized in relatively large quantities in Finland
and the Netherlands and there is evidence that, in the latter seizure, the 2C-H was intended as a precursor for the
production of 2C-I.
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United Kingdom (B): one case of a seizure in 1999.
Sweden (B): one seizure in 1999.
Reports to Europol
Two Member States, Germany and Sweden, reported incidental, small-scale
production, in 1999, of 2C-I in kitchen-type facilities.
Three Member States, Denmark, Germany and Sweden, reported seizures of 2C-I.
The German and Swedish seizures related to the seized kitchen-type facilities.
2C-T-2
Chemical and physical description
Chemical name: 4-ethylthio-2,5-dimethoxyphenethylamine
Chemical structure:
2C-T-2                          2C-T-7  
Molecular formula: C12H19NO2S
Synonyms: 4-ethylthio-2,5-dimethoxyphenethylamine
4-ethylsulfanyl-2,5-dimethoxyphenethylazan (Germany)
Street name: ‘2C-T-2’
Pharmaceutical form: mostly tablet form; sometimes powder form (hydrochloride salt)
Identification: slightly more orange colour using the Marquis reagent assay compared
to a slightly more red colour with 2C-T-7 (Erowid, 2001)
CH3O NH2
OCH3SH3C
CH3O NH2
OCH3S
H3C
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Routes of administration, dose and duration
Routes of administration: oral or intranasal (insufflation/snorting)
Common dose range: 10 to 35 mg (average = 20 mg orally; 13 mg intranasally)
Duration: 6 to 8 hours
Effects
The effects of 2C-T-2 are very similar to 2C-T-7. The effects of 2C-T-2 seem to share
some general similarities with mescaline or 2C-B.
‘There is a considerable parallel between 2C-T-2 and 2C-T-7... With 2C-T-2, there is
more of a tendency to have physical disturbances such as nausea and diarrhoea.
And the experience is distinctly shorter.’ (A. Shulgin)
Health risks
As with the other 24 drugs of the 2C-T family, 2C-T-2’s clinical safety profile is not
well known nor has it been adequately researched. The most severe side-effects,
according to user reports, are nausea, vomiting, delirium, dissociation, loss of
memory, panic attacks and a strong depression of CNS, which could induce
convulsions or suffocation or lead to physical injury. Combining 2C-T-2 with MDMA
increases the risk to health.
Similarly to 2C-T-7, ‘snorting’ the drug in powder form increases the secondary
effects and the risk of overdose. Combining 2C-T-2 with MAOIs (commonly found in a
number of antidepressants) is potentially dangerous (risk of serotonergic syndrome).
There have been no reported fatalities in the EU.
Legitimate uses for 2C-T-2
There are no known licensed therapeutic uses for 2C-T-2.
66
Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs
Legal status (9)
2C-T-2 is a ring-substituted phenethylamine, which is currently not listed under any of
the schedules of the 1971 UN Convention on Psychotropic Substances.
In Germany, 2C-T-2 was placed under Schedule I on 7 October 1998 (listed as 4-
ethylsulfanyl-2,5-dimethoxyphenethylazan).
In Sweden, 2C-T-2 was placed under ‘emergency scheduling’ on 1 April 1999.
In the Netherlands, 2C-T-2 has been classified as an unregistered pharmaceutical
since 12 April 1999. The unlicensed manufacture, sale, import, trade and possession
of this substance is liable for prosecution.
2C-T-2 is not controlled in the USA.
Reports to the EMCDDA
(A = reporting form; B = other)
France (A): notification on 23 September 2002 (seizure of one white
tablet, no logo, sold as ‘mescaline’), collected by Sintes
(the national poison/substance identification system) in
August 2002.
Germany (A): notification in March 1998 of several seizures reported
by BKA in February 1998 of a total of 20 tablets 
(170 mg) with an ‘X’ logo.
Sweden (A): notification on 15 January 1999 of one seizure of 
0.07 gm of powder on 10 July 1998.
Sweden (B): six seizures in 1998, three seizures in 1999, two in
2000, one in 2001.
(9) Since the finalisation of this report, 2C-T-2 has been made a subject of control in France (Judgment, 13 October 2003,
OJ 246, 23.10.2003, p. 18032, Annex 4).
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Denmark (B): a seizure of 2 000 tablets on 26 January 2001.
The Netherlands (B): mentioned in the DIMS report in 1998.
Spain (B): one mention in 1998.
Reports to Europol
One Member State, Germany, reported incidental, small-scale production, in 1999, of
2C-T-2 in a kitchen-type facility.
Five Member States, Denmark, Germany, France, Finland and Sweden, reported small
seizures of 2C-T-2. The German seizure related to the seized kitchen-type facility.
One Member State, Denmark, reported on a case of international trafficking of 
2C-T-2 through the mail system. The drugs originated in the Netherlands.
2C-T-7
Chemical and physical description
Chemical name: 2,5-dimethoxy-4-(n)-propylthiophenethylamine
Chemical structure:
2C-T-7                      2C-T-2
Molecular formula: C13H21NO2S
Synonyms: 4-propylthio-2,5-dimethoxy-phenethylamine (PT-DM-PEA)
Street names: ‘T-seven’, ‘Beautiful’, ‘Lucky seven’, ‘Seven-up’, ‘Seventh heaven’,
‘Tweety bird mescaline’, ‘Tripstasy’ (US), ‘Red raspberry’ (Canada), ‘Blue mystic’
(brand name in the Netherlands; has ‘Yin-yang’ logo)
Pharmaceutical form: powder form (hydrochloride salt) or capsule/tablet
CH3O NH2
OCH3S
H3C
CH3O NH2
OCH3SH3C
68
Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs
Identification: slow/weak ‘salmon orange’ (pink, orange-red) colour using the
Marquis reagent assay (Erowid)
Routes of administration, dose and duration
Routes of administration: oral (most common route) or intranasal
(insufflation/snorting)
Dose range: 10 to 30 mg orally; 2.5 to 35 mg intranasally
Duration of action: 5 to 12 hours
Effects
As with 2C-T-2 and 2C-I, the effects of 2C-T-7 are described as classically
psychedelic, sharing some of the characteristics of mescaline and 2C-B.
‘Individual sensitivities seem to vary greatly with 2C-T-7, in sharp contrast to 2C-T-2’.
(synthesis of user reports by Murple/Erowid, February 2001)
Health risks
2C-T-7’s clinical safety profile has not been adequately researched and is not well
known. User reports exhibit a lot of conflicting and confusing information, including
about the duration of action, physical stimulation, dose, etc. Because this drug
appears to be highly dose-sensitive, users should be extremely careful with dosage.
2C-T-7 can cause unexpected side-effects and this increases with high doses: nausea,
diarrhoea, vomiting, delirium, dissociation, loss of memory, panic attacks and a
strong depression of CNS, which could induce convulsions or suffocation or lead to
physical injury. Combining 2C-T-7 with MDMA may pose a significant health risk.
Snorting the drug in powder form is recognised as being the most dangerous route,
as it increases the secondary effects and the risk of severe (even lethal) overdose.
Combining 2C-T-7 with MAOIs is potentially dangerous (MAOIs are commonly found
in antidepressants such as phenelzine, tranylcypromine, isocarboxazid, l-deprenyl
and moclobemide). As with other psychedelics, 2C-T-7 may trigger latent
psychological and mental problems.
There have been no reported fatalities in the EU.
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In the USA, three deaths involving 2C-T-7 have been reported: one in October 2000
(35 mg, snorted) and two in April 2001 (2C-T-7 combined with MDMA).
Legitimate uses for 2C-T-7
There are no known licensed therapeutic uses for 2C-T-7.
Legal status (10)
2C-T-7 is a ring-substituted phenethylamine, which is currently not listed under any of
the schedules of the 1971 UN Convention on Psychotropic Substances.
In Germany, 2C-T-7 was placed under control on 20 January 1998.
In Sweden, this drug is controlled under the emergency list.
In the United Kingdom and Ireland, 2C-T-7 is a Class A drug.
In the USA, in September 2002, the DEA issued a final order to place 2C-T-7
temporarily under Schedule I. This temporary scheduling will last up to 18 months or
until the drug is permanently scheduled. 2C-T-7 is also controlled in Canada.
Reports to the EMCDDA
(A = reporting form; B = other)
France (A): notification on 21 February 2001 of one seizure (on 12
February 2001) of three blue tablets (‘Blue mystic’, with
‘Yin-yang’ logo) weighing 256 mg each, with 10 mg of
the active compound.
Finland (B): one case of seven blue tablets (‘Blue mystic’, with ‘Yin-
yang’ logo) in 2002.
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(10) Since the finalisation of this report, 2C-T-7 has been made a subject of control in France (Judgment, 13 October 2003,
OJ 246, 23.10.2003, p. 18032, Annex 4).
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United Kingdom (B): report in January 2002 of one case of three tablets
collected in a London club amnesty bin in January 2001
(first case in the United Kingdom).
Germany (B): one seizure in 2001 of one 2C-T-7 pill (20 mg).
Sweden (B): one seizure in 1999, one seizure in 2000, one in 2001.
Reports to Europol
One Member State, Germany, reported incidental, small-scale production, in 1999, of
2C-T-7 in a kitchen-type facility.
Four Member States, Germany, France, Finland and Sweden, reported on small
seizures of 2C-T-7. The German seizure related to the seized kitchen-type facility.
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Chapter 3
Review of the pharmacotoxicological data on
2C-I (11)
Very limited data for 2C-I have been published in peer-reviewed scientific journals.
The following information includes studies involving structurally related compounds
and user-based evidence (Information Classification IV, EMCDDA, 1999).
Chemical and pharmaceutical information
Chemical description
The chemical structure of 2,5-dimethoxy-4-iodophenethylamine (2C-I) is shown in
Figure 1. Other chemical names include 4-iodo-2,5-dimethoxyphenethylamine, (2,5-
dimethoxy-4-iodophenyl)-2-aminoethane and 4-iod-2,5-dimethoxyphenethylazan. The
abbreviation ‘2C-I’ is derived from the nomenclature according to Shulgin and
Shulgin (1991), with the ‘-I’ referring to the presence of an iodine atom that has no
additional branching, unlike the 2C-Ts (Pihkal No 33).
Chemical structure of 2C-I
Molecular formula: C10H14INO2
Molecular weight: 307
There is no chemical abstracts registration (CAS) number for 2C-I. 2C-I hydrochloride
is a white microcrystalline solid.
(11) This report was written by S. P. Elliott of the Regional Laboratory for Toxicology (City Hospital, Birmingham, United
Kingdom) for the risk assessment meeting on 2C-I held in Lisbon on 31 March and 1 April 2003. Help and information
was provided by: S. Ahlstrom, D. Corrigan, C. Furnari, J. Idanpaa-Heikkila, M. Mallaret, C. Poethko-Muller, J-P. Tassin,
A. Wallon, R. Wennig, L. Westberg. The report was commissioned by the EMCDDA as a background paper for the risk
assessment of the compound 2C-I. The report follows the structure of Annexes A and B of the risk assessment guidelines
developed by the Scientific Committee of the EMCDDA.
CH3O NH2
OCH3I
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Methods of synthesis
The synthesis of 2C-I is described in Pihkal, based on the initial use of 2,5-
dimethoxybenzaldehyde to produce a preliminary precursor, 2,5-
dimethoxyphenethylamine (2C-H) (Shulgin and Shulgin, 1991). The former
compound, 2,5-dimethoxybenzaldehyde, is commercially available. The method is
extensive, requiring specialist equipment and an appropriate environment. There is no
information available about the exact method of synthesis used by clandestine
laboratories.
Identification
There is no published information regarding the analytical profile of 2C-I. However,
data pertaining to gas chromatography with mass spectrometry (GC-MS), high
performance liquid chromatography with mass spectrometry (HPLC-MS), nuclear
magnetic resonance (NMR) and Fourier transform infrared spectroscopy (FTIR) have
been obtained (Bernhard, 2002). Like 2C-T compounds, 2C-I would not be expected
to be detected by commonly used immunoassay procedures for the preliminary
identification of amphetamines in urine (particularly based on monoclonal
antibodies).
Legitimate uses of 2C-I
There are no known licensed therapeutic uses for 2C-I.
Pharmaceutical form
2C-I is typically available in powder or tablet form, although 2C-I in liquid form has
also been noted by the Danish focal point. A tablet seized in Denmark in 2002 was
white in appearance, had an ‘i’ logo and was approximately 6.1 x 2.7 mm,
weighing 120 mg.
Routes of administration and dosage
As 2C-I is obtained in powder or tablet form, the primary route of administration is
oral. Insufflation (snorting) and other routes (e.g. intravenous administration)
associated with 2C-T-2 and 2C-T-7 (Murple, 2001) are not mentioned in 2C-I user
reports (Erowid, 2001–03).
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Original studies by Shulgin and Shulgin (1991) involved oral administration of 2C-I in
doses of between 15 and 20 mg. This is compared to a Pihkal ‘recommended’ dose
of 80 to 150 mg for MDMA, 178 to 256 mg for mescaline (hydrochloride), 12 to
24 mg for 2C-B, 60 to 100 mg for 2C-T, 10 to 30 mg for 2C-T-7, 1 to 3 mg for DOB
and 3 to 10 mg for DOM (Shulgin and Shulgin, 1991) and a Tihkal ‘recommended’
dose of 0.06 to 0.2 mg for LSD (Shulgin and Shulgin, 1997). User reports have
mentioned oral doses of between 3 and 25 mg (typically 20 mg) (Erowid, 2001–03).
It should be noted, however, that the accuracy of such reports are dependent on user
honesty and accurate weighing of the compound or knowledge of the actual
content/weight of the tablet/powder’s constituents.
Toxicology and pharmacology in animals and humans
Very limited data for 2C-I have been published in peer-reviewed scientific journals.
Consequently, the following information includes speculative comparison with partially
related compounds such as 2C-B (which is phenethylamine based) and DOB (which is
amphetamine based), both involving bromine as opposed to iodine. It is
inappropriate to compare data derived from MDMA, PMA and 4-MTA studies, due to
the absence of 2,5-dimethoxy substituent groups in such compounds.
Neuropharmacology
Previous studies by Lobos et al. (1992) involving a bromine-substituted analogue, 
2C-B (4-bromo-2,5-dimethoxyphenethylamine), have shown it to be a partial agonist
for 5-HT2 (5-HT2A and 5-HT2C) serotonergic receptors and 1-adrenergic receptors. At
10-6M, 2C-B also acted as a competitive 5-HT antagonist but, at higher concentrations
(2.8 x 10-5M), it acted as a non-competitive 5-HT antagonist (Lobos et al., 1992). In
addition, Glennon et al. (1988) found that DOB (4-bromo-2,5-
dimethoxyamphetamine) had a high affinity for 5-HT2 receptors, whereas 2C-B was
also found to have significant affinity for 5-HT1A, 5-HT1B and 5-HT1C receptors and thus
was deemed to be less selective than its amphetamine-based analogue, DOB.
Therefore, as 2C-I is more structurally related to 2C-B, it is possible it may have a
similar serotonergic receptor affinity (i.e. binding to 5-HT2 and, to some degree, 
5-HT1 receptors). Recently, Acuna-Castillo et al. (2002) found that 2C-I had higher
agonistic efficacy at 5-HT2C receptors compared to 5-HT2A receptors. However, the
relative efficacy was lower than the phenylisopropylamines also studied (including
76
Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs
2,5-dimethoxy-4-iodophenyliospropylamine). Previously, researchers have provided
evidence for the involvement of 5-HT2 serotonergic receptors (in particular 5-HT2A) in
the action of hallucinogenic agents (Glennon et al., 1984). In particular, using radio-
labelled (125I)-2-C-I, Johnson et al. (1990) showed that the 5-HT receptor is
significantly linked to hallucinogenic activity (Johnson et al.). Despite the initial
information for 2C-I indicating it to be a potential 5-HT2C (and, to a lower extent, 
5-HT2A) receptor agonist, further studies are required before definitive conclusions can
be drawn.
Neuroendocrinology
No specific research has been conducted on 2C-I. Serotonin agonists stimulate
hypothalamic neurons involved in ACTH and cortisol secretion (Fuller, 1981), in
addition to stimulating growth hormone and prolactin secretion (as evidenced by
mescaline and DOM) (Demisch and Neubauer, 1979; Meltzer et al., 1978). It is
possible, therefore, that 2C-I may produce similar effects on hormonal secretion.
Cardiovascular and thermoregulatory responses
No specific research has been conducted on 2C-I. There is also only very limited
subjective evidence available from user surveys, which indicates varying observations
for these clinical features.
Toxicology
At present there are no animal or human data concerning the general toxicity,
reproductive toxicity, neurotoxicity or the mutagenicity and carcinogenic potential of
2C-I.
Toxicity in animals
Shulgin and Shulgin (1991) reported on studies on mice involving intraperitoneal
(i.p.) administration of DOB and found the LD50 to be between 100 and 125 mg/kg.
Administration of 50 mg/kg (i.p.) resulted in twitching, 100 mg/kg produced
shaking, and mice receiving >125 mg/kg exhibited convulsions and eventually died.
No such studies have been performed for 2C-I and, due to the structural differences
between DOB and 2C-I (which is likely to alter the toxicity of the respective
compounds), such data are not directly comparable. In particular, Shulgin describes 
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2 mg as an effective dose for DOB but suggests that 14 to 22 mg may be required
using 2C-I.
Toxicity in humans
As mentioned above, only subjective evidence is available from a small number of
user reports on the apparent adverse effects and toxic symptoms of 2C-I.
In general, although users have described 2C-I as a ‘powerful’ and ‘strong stimulant’
with hallucinogenic properties (Erowid, 2001–03), users purporting to have taken
only 2C-I make virtually no mention of adverse effects such as nausea, vomiting and
muscle cramps, as reported for 2C-T-2 and 2C-T-7 (Erowid, 2001–03; Murple,
2001). However, this may be due to selective reporting rather than absence of such
symptoms. Nevertheless, some users reported stomach tension, nausea, vomiting and
jaw tension when combining 2C-I with one or more of the following: 5-methoxy-
dipropyltryptamine, cannabis, alcohol, caffeine, tryptophan, alprazolam and
clonazepam.
Users have noted that the desired effect of 2C-I may be delayed, with the result that a
user may take additional (sometimes higher) doses, which could result in accidental
overdose.
Interactions with other drugs or medicines
Unlike other phenethylamine derivatives, including 2C-B (De Boer et al., 1999), it
appears that 2C-I is not usually present in tablets containing other phenethylamines or
stimulants. This therefore reduces the possibility of concomitant ingestion of other
drugs in illicit preparations. However, as the pharmacology of 2C-I is largely
unknown, it is difficult to predict with accuracy any particular potential drug
interactions or contraindications. Winter et al. (1999) studied the acute effects of
monoamine reuptake inhibitors (SSRIs such as fluvoxamine, fluoxetine and
venlafaxine) on the stimulus effects of hallucinogens (including DOM) and observed
an additivity of effects rather than a potentiation. It is possible, therefore, that similar
effects may occur with 2C-I. Some users report concomitant use with other drugs (e.g.
5-methoxy-dipropyltryptamine, cannabis, alcohol, caffeine, tryptophan, alprazolam
and clonazepam), but there is a lack of specific evidence. However, in some cases this
did result in toxic effects (see the section entitled ‘Toxicity in humans’).
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Non-fatal cases of 2C-I intoxication in humans
Like the 2C-Ts, 2C-I is not usually detected during routine toxicological analysis (this is
typically due to the lack of any reference material). The evidence for use is usually
based on anecdotal or circumstantial evidence (if any information is available to
medical staff at all). There have been no reported instances of non-fatal intoxication
involving the use of 2C-I.
Fatal cases of 2C-I intoxication in humans
Unlike 2C-T-7, there have been no reported fatalities implicating 2C-I. However, the
lack of reference material may compromise clinical toxicological investigations during
post-mortems.
Pharmacokinetics and metabolism
No specific research has been conducted on 2C-I. However, metabolic studies of 2C-B
have been performed on rats and by analysis of human urine (De Boer et al., 1998;
Kanamori et al., 2002). Kanamori et al. identified two pathways in the rat involving
(a) initial deamination followed by reduction or oxidation; and (b) 2- or 5-position O-
desmethylation followed by amino acetylation (Kanamori et al., 2002). De Boer et al.
(1998) identified unchanged parent compound (i.e. 2C-B) in addition to 4-bromo-
2,5-dimethoxyphenylacetic acid, 4-bromo-2,5-dimethoxybenzoic acid and 4-bromo-
5-hydroxy-2-methoxyphenethylamine in the urine of 2C-B users. It is likely that
metabolism of 2C-I may proceed via similar pathways, probably involving oxidative
deamination (I, II) and O-desmethylation of the aromatic methoxy groups (III) in
addition to excretion of unchanged drug (the possibility of species-dependent
metabolism notwithstanding). This would lead to the corresponding compounds:
I = 2,5-dimethoxy-4-iodophenylacetic acid
II = 2,5-dimethoxy-4-iodobenzoic acid
III = 4-iodo-5-hydroxy-2-methoxyphenethylamine
However, additional metabolic reactions are a possibility, particularly potential N-
acetylation (as observed in rats by Kanamori et al., 2002).
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Anecdotal evidence from users indicates an onset of initial action of one to two hours.
However, some users report slower desired effects compared to related drugs (e.g.
2C-B) or MDMA. The effects are typically described as lasting for up to 10 hours
post-oral dose (Shulgin and Shulgin, 1991; Erowid, 2001–03). This compares to a
duration of action of 8 to 12 hours for orally ingested LSD and 10 to 12 hours for
mescaline (Shulgin and Shulgin, 1991).
Clinical experience
2C-I has not undergone any clinical or pre-clinical evaluation studies. The majority of
data is based on self-reporting by users.
Studies on street users
Unlike 2C-T-2 and 2C-T-7, there have been no studies involving 2C-I users. There
have been a small number of isolated user reports, which, in general, compare 2C-I
to 2C-B due to an apparent similarity in their effects, although some users describe
2C-I as being ‘deeper, more purely psychedelic and less sensory’ and, in some cases,
less intense (Shulgin and Shulgin, 1991; Erowid, 2001–03). Hallucinogenic and
visual responses have been reported, in addition to feelings of empathy described as
similar to those produced by MDMA. As mentioned above, various users report
delayed desired effects compared to related drugs (e.g. 2C-B) or MDMA (Erowid,
2001–03).
Overall, the small number of subjective user reports available indicate that 2C-I
produces various psychedelic effects (comparable to other hallucinogens, particularly
2C-B) and feelings of empathy (similar to MDMA). A delayed onset of effects has
been described.
Dependence potential in humans
Tolerance
No specific research has been conducted on 2C-I. In addition, no user reports appear
to have mentioned the occurrence or absence of tolerance to the effects of 2C-I
(Erowid, 2001–03). If tolerance does occur, it is possible that cross-tolerance could
occur between other related psychedelic phenethylamines such as 2C-T-2, 2C-T-7, 
2C-B and mescaline.
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Dependence potential
No specific research has been conducted on 2C-I. Although the specific
pharmacology of 2C-I is unknown, speculative comparison with related compounds
suggests that it is unlikely to produce physical dependence or addiction such as that
which occurs with opiate use. However, without specific study, definitive conclusions
cannot be drawn.
Psychological risk assessment (cognition, mood and mental functioning)
Acute and chronic effects
There are no published data on the specific psychological effects of 2C-I, acute or
chronic. As described in the pharmacological report, limited anecdotal user reports
describe a few subjective psychological effects that occur with 2C-I use (Erowid,
2001–03). Such reports mention a general clarity of thought with little or no
‘psychological after-effects’. However, some introspection and ‘negative thought-loops’
were described by some users.
Conclusions
• 2C-I is a synthetic drug which was first synthesised by Shulgin.
• Seized/available material includes powder, tablets (white, ‘i’ logo) and liquid
preparations.
• 2C-I has no licensed therapeutic or industrial use.
• 2C-I is a confirmed 5-HT2C and 5-HT2A receptor agonist, in addition to potential 
5-HT1 and 1-adrenergic receptor affinity.
• Users report stimulant effects, hallucinogenic/visual effects (similar to 2C-B) and
emotional/empathetic responses (similar to MDMA). There is very little information
regarding adverse effects.
• Due to the lack of specific scientific evidence, acute or chronic toxicity of 2C-I has
not been confirmed in humans, but toxic effects cannot be excluded.
• Anecdotal reports from users suggest that 2C-I might have an unexpected slower
onset of desired effects compared to related drugs (e.g. 2C-B) or MDMA. This may
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result in some users taking additional doses or other drugs, which may increase the
risk of toxicity or overdose.
• There have been no reported cases of fatal or non-fatal intoxication.
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Review of the pharmacotoxicological data 
on 2C-T-2 (12)
Very limited data for 2C-T-2 have been published in peer-reviewed scientific journals.
The following information includes studies involving structurally related compounds
and user-based evidence (Information Classification IV, EMCDDA, 1999).
Chemical and pharmaceutical information
Chemical description
The chemical structure of 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) is shown
in Figure 1. Other chemical names include 4-ethylthio-2,5-dimethoxyphenethylamine
and 4-ethylsulfanyl-2,5-dimethoxyphenethylazan. The abbreviation ‘2C-T-2’ is derived
from the nomenclature according to Shulgin and Shulgin (1991), and, although this
compound has less carbons than 2C-T-7, the ‘-2’ part of the abbreviation has no
structural significance but refers only to the historical order of study/discovery (Pihkal
No 40).
Chemical structure of 2C-T-2
Molecular formula: C12H19NO2S
Molecular weight: 241.35
There is no chemical abstracts registration (CAS) number for 2C-T-2. 2C-T-2
hydrochloride is a white crystalline solid.
CH3O NH2
OCH3SH3C
(12) This report was written by S. P. Elliott of the Regional Laboratory for Toxicology (City Hospital, Birmingham, United
Kingdom) for the risk assessment meeting on 2C-T-2 held in Lisbon on 31 March and 1 April 2003. Help and
information was provided by: S. Ahlstrom, D. Corrigan, C. Furnari, J. Idanpaa-Heikkila, M. Mallaret, C. Poethko-Muller,
J-P. Tassin, A. Wallon, R. Wennig, L. Westberg. The report was commissioned by the EMCDDA as a background paper
for the risk assessment of the compound 2C-T-2. The report follows the structure of Annexes A and B of the risk
assessment guidelines developed by the Scientific Committee of the EMCDDA.
84
Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs
Methods of synthesis
It is thought that 2C-T-2 was first synthesised in 1981 by Shulgin (Erowid, 2001). 
A synthesis protocol was later described in Pihkal based on initial use of 
1,4-dimethoxybenzene to produce a preliminary precursor, 2,5-dimethoxythiophenol
(Shulgin and Shulgin, 1991). Shulgin describes the latter compound as a ‘valuable
precursor to all members of the 2C-T family’ and this is now commercially available
(Poortman, 1999). The method is extensive, requiring specialist equipment and an
appropriate environment. Poortman analysed chemicals/material seized from a
clandestine laboratory where the intermediate substances and final product pertaining
to the Shulgin synthetic methodology for 2C-T-2 were identified (Poortman, 1999).
Identification
2C-T-2 apparently exhibits a slightly more orange colour using the Marquis reagent
assay compared to the slightly more red colour obtained with 2C-T-7 (Erowid, 2001).
There is minimal information regarding the analytical profile of 2C-T-2 using common
methods such as gas chromatography with mass spectrometry (GC-MS), or nitrogen-
phosphorus detection (GC-NPD), or high-performance liquid chromatography with
diode-array detection (HPLC-DAD). Electron impact (EI) mass spectral data (without
any chemical derivatisation) has indicated major abundant ions of 212, 183, 241
(molecular ion), 153 and 197 (in order of abundance) (Poortman, 1999). Bosman et
al. (1998) also presented GC-MS data. In addition, Fourier transform infrared
spectroscopy (FTIR) data have been described (Poortman, 1999). Like 2C-T-7, 2C-T-2
would not be expected to be detected by commonly used immunoassay procedures
for the preliminary identification of amphetamines in urine (particularly based on
monoclonal antibodies).
Legitimate uses of 2C-T-2
There are no known licensed therapeutic or industrial uses for 2C-T-2. However, there
is some information indicating its use in ‘psychedelic therapy’ (Shulgin and Shulgin,
1991; Stolaroff and Wells, 1993; Murple, 2001).
Pharmaceutical form
2C-T-2 is typically available in powder or tablet form. No associated ‘street names’
have been reported specifically relating to 2C-T-2. Between 1997 and 1999, 2C-T-2
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was sold in Dutch smartshops purporting to be 2C-T-7 or ‘S5’ (4-MTA). It is also
believed that it was sold in similar shops in Sweden in 1999. More recently,
information from national Reitox centres has indicated that tablets have been seized
which are white in appearance, have no logo and are approximately 8.5 to
8.8 mm x 3.4 to 3.7 mm, weighing 247 to 249 mg (France and Denmark).
The purchase price varies but is largely comparable to other phenethylamine
derivatives such as MDMA (typically EUR 5 to 20) (Erowid, 2002).
Routes of administration and dosage
As 2C-T-2 is obtained in powder or tablet form, the primary route of administration is
oral, but insufflation (snorting) is also frequently mentioned in user reports (Murple,
2001). In the Murple survey of 43 self-reporting 2C-T-2 users, respondents indicated
that their usual routes of administration were oral (83.7 %) and intranasal (16.3 %).
Unlike 2C-T-7, smoking, rectal and intravenous/intramuscular administration were not
mentioned.
Original studies by Shulgin and Shulgin (1991) involved oral administration of doses
of 2C-T-2 of 12 to 25 mg (Shulgin and Shulgin, 1991). This is compared to a Pihkal
‘recommended’ dose of 80 to 150 mg for MDMA, 178 to 256 mg for mescaline
(hydrochloride), 12 to 24 mg for 2C-B, 60 to 100 mg for 2C-T, 10 to 30 mg for 
2C-T-7, 1 to 3 mg for DOB and 3 to 10 mg for DOM (Shulgin and Shulgin, 1991)
and a Tihkal ‘recommended’ dose of 0.06 to 0.2 mg for LSD (Shulgin and Shulgin,
1997). Respondents in a user survey mentioned oral doses of 5 to 40 mg (average
21 mg) and intranasal doses of 2.5 to 35 mg (average 13 mg) (Murple, 2001). By
implication, the wide-ranging doses mentioned for 2C-T-7 may indicate that there is
less individual sensitivity to 2C-T-2. It should be noted, however, that the accuracy of
the statements about dosage collated by Murple is dependent on user honesty and
accurate weighing of the compound or knowledge of the actual content/weight of the
tablet/powder’s constituents.
Toxicology and pharmacology in animals and humans
No data for 2C-T-2 have been published in peer-reviewed scientific journals. The
following information is based on speculative comparison with partially related
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compounds such as 2C-B (which is phenethylamine based) and DOB (which is
amphetamine based), both involving bromine as opposed to sulphur. It is
inappropriate to compare data derived from MDMA, PMA and 4-MTA studies, due to
the absence of 2,5-dimethoxy substituent groups in such compounds.
Neuropharmacology
No specific research has been conducted on 2C-T-2. Studies by Lobos et al. (1992)
involving a bromine-substituted analogue, 2C-B (4-bromo-2,5-
dimethoxyphenethylamine), have shown it to be a partial agonist for 5-HT2 (5-HT2A
and 5-HT2C) serotonergic receptors and 1-adrenergic receptors. At 10-6M, 2C-B also
acted as a competitive 5-HT antagonist, but, at higher concentrations (2.8 x 10-5M), it
acted as a non-competitive 5-HT antagonist (Lobos et al., 1992). An amphetamine-
based analogue of 2C-T-2, ALEPH-2 (2,5-dimethoxy-4-ethylthioamphetamine), was
also found to be a partial agonist of 5-HT2A and a full agonist of 5-HT2C (Acuna-
Castillo et al., 2000). In addition, Glennon et al. (1988) found that DOB (4-bromo-
2,5-dimethoxyamphetamine) had a high affinity for 5-HT2 receptors, whereas 2C-B
was also found to have significant affinity for 5-HT1A, 5-HT1B and 5-HT1C receptors and
thus was deemed to be less selective than its amphetamine-based analogue, DOB.
Therefore, as 2C-T-2 is phenethylamine based, it is possible it may have serotonergic
receptor affinity similar to 2C-B (i.e. binding to 5-HT2 and, to some degree, 5-HT1
receptors). Researchers have already provided evidence of the involvement of 5-HT2
serotonergic receptors (in particular 5-HT2A) in the action of hallucinogenic agents
(Glennon et al., 1984). It is conceivable, therefore, that the apparent hallucinogenic
effects of 2C-T-2 may be related to similar receptor affinities. However, such
conjecture is only based on limited information on related compounds and further
studies of 2C-T-2 are required before definitive conclusions can be drawn.
Neuroendocrinology
No specific research has been conducted on 2C-T-2. Serotonin agonists stimulate
hypothalamic neurons involved in ACTH and cortisol secretion (Fuller, 1981), in
addition to stimulating growth hormone and prolactin secretion (as evidenced by
mescaline and DOM) (Meltzer et al., 1978, 1981; Demisch and Neubauer, 1979). It
is possible, therefore, that 2C-T-2 may produce similar effects on hormonal secretion.
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Cardiovascular and thermoregulatory responses
No specific research has been conducted on 2C-T-2. Only subjective evidence is
available from user surveys, showing a variety of observations on cardiovascular and
thermoregulatory responses. However, the sample size of the Murple survey was
smaller than the one for 2C-T-7.
User comments collated by Murple (2001) indicated that 16.3 % experienced
tachycardia and 2.3 % experienced hypertension (both largely route independent). It
is doubtful, however, that users had access to blood pressure and heart rate monitors
for medical confirmation of these symptoms. Compared to 2C-T-7, where 31.9 % of
users noted headaches (indicating possible increased blood pressure), only 9.3 %
reported headaches with 2C-T-2 (Murple, 2001).
Although various (inconsistent) observations regarding effects on body temperature
were described by Murple, this information appears to be associated with 2C-T-7, not
2C-T-2.
Toxicology
At present, there are no animal or human data concerning the general toxicity,
reproductive toxicity, neurotoxicity or the mutagenicity and carcinogenic potential of
2C-T-2.
Toxicity in animals
Shulgin and Shulgin (1991) reported on studies on mice involving intraperitoneal
(i.p.) administration of DOB and found the LD50 to be between 100 and 125 mg/kg.
Administration of 50 mg/kg (i.p.) resulted in twitching, 100 mg/kg produced
shaking, and mice receiving >125 mg/kg exhibited convulsions and eventually died.
No such studies have been performed for 2C-T-2 and, due to the significant structural
differences between DOB and 2C-T-2 (which is likely to alter the toxicity of the
respective compounds), such data are not directly comparable. In particular, Shulgin
describes 2 mg as an effective dose for DOB but suggests that 12 to 25 mg may be
required using 2C-T-2.
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Toxicity in humans
As mentioned above, only subjective evidence is available from user surveys on the
apparent adverse effects and toxic symptoms of 2C-T-2. In a study of 43 self-
reporting 2C-T-2 users described by Murple (2001), side-effects of varying degrees
were noted in approximately 81 % of users. Of these, none was prolonged or severe,
compared to 3 % with 2C-T-7. The most common side-effect was nausea (60.5 %),
followed by muscle tension (32.6 %), vomiting (23.3 %), diarrhoea (18.6 %),
tachycardia (16.3 %), dehydration (16.3 %; probably related to diarrhoea/vomiting
or the administration situation/environment), headaches (9.3 %), hypertension (2.3 %)
and, to a smaller extent, some stomach ache and confusion. It should be noted that,
overall, there were less adverse effects with 2C-T-2 compared to 2C-T-7. However, the
2C-T-2 study was far smaller (43 respondents) than the 2C-T-7 study (423
respondents). Similar adverse symptoms were reported in a study by Stolaroff and
Wells (1993), particularly nausea, vomiting and muscle tension/spasms, but there
were less cardiac effects.
Interactions with other drugs or medicines
Unlike other phenethylamine derivatives, including 2C-B, it appears that 2C-T-2 is not
usually present in tablets containing other phenethylamines or stimulants (De Boer et
al., 1999; Erowid, 2000). This therefore reduces the possibility of concomitant
ingestion of other drugs in such illicit preparations. However, as the pharmacology of
2C-T-2 is largely unknown, it is difficult to predict with accuracy any particular
potential drug interactions or contraindications. Winter et al. (1999) studied the acute
effects of monoamine reuptake inhibitors (SSRIs such as fluvoxamine, fluoxetine and
venlafaxine) on the stimulus effects of hallucinogens (including DOM) and observed
an additivity of effects rather than a potentiation. It is possible, therefore, that similar
effects may occur with 2C-T-2. Some user reports collated by Murple have mentioned
the concurrent use of other drugs (Murple, 2001). Other psychedelic drugs apparently
produced synergistic effects, whereas benzodiazepines and GHB produced anxiolytic
and sedative effects. Like 2C-T-7, stimulants appeared to be potentiated by 2C-T-2.
There were a number of individual comments made by users regarding single drugs,
but these have not been included in this report. Despite the concomitant use of MDMA
by some users, there was no information indicating enhanced MDMA toxicity due to
direct (e.g. synergistic) or indirect (e.g. metabolic) effects. In addition, potential
adverse interaction with monoamine oxidase inhibitors (MAOIs) has been mentioned
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(Murple, 2001). However, no specific studies have been conducted on the effects of
such drugs when administered with 2C-T-2, so these and the other potential
interactions described above have not been confirmed.
Non-fatal cases of 2C-T-2 intoxication in humans
There have been no reported instances of non-fatal intoxication involving the use of
2C-T-2. It is not usually detected during routine toxicological analysis (typically due to
the lack of any reference material), and the indication of use is usually based on
anecdotal or circumstantial evidence (if any information is available to medical staff
at all).
Fatal cases of 2C-T-2 intoxication in humans
There have been no reported fatalities implicating 2C-T-2. However, the lack of
reference material may compromise the analysis of post-mortem cases when
conducting clinical toxicological investigations.
Pharmacokinetics and metabolism
No specific research has been conducted on 2C-T-2. However, metabolic studies using
2C-B have been conducted on rats and on human urine (De Boer et al., 1998;
Kanamori et al., 2002). Kanamori et al. (2002) identified two pathways in the rat
involving (a) initial deamination followed by reduction or oxidation; and (b) 2- or 
5-position O-desmethylation followed by amino acetylation. De Boer et al. (1998)
identified the unchanged parent compound (i.e. 2C-B) and 4-bromo-2,5-
dimethoxyphenylacetic acid, 4-bromo-2,5-dimethoxybenzoic acid and 4-bromo-
5-hydroxy-2-methoxyphenethylamine in the urine of 2C-B users. It is likely that
metabolism of 2C-T-2 may proceed via similar pathways, probably involving
oxidative deamination (I, II) and O-desmethylation of the aromatic methoxy groups
(III), in addition to excretion of unchanged drug (the possibility of species-dependent
metabolism notwithstanding). This would lead to the corresponding compounds:
I = 2,5-dimethoxy-4-ethylthiophenylacetic acid
II = 2,5-dimethoxy-4-ethylthiobenzoic acid
III = 4-ethylthio-5-hydroxy-2-methoxyphenethylamine
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However, additional metabolic reactions are a possibility, particularly involving the
ethylthio moiety at the 4-position or (as observed in rats by Kanamori et al., 2002)
potential N-acetylation.
Anecdotal evidence from users indicates an onset of action of one to two hours, with
effects lasting up to 6 to 8 hours (Murple, 2001). However, these data typically refer
to oral ingestion and user comments indicate more rapid onset and shorter duration
of effects following insufflation (Murple, 2001). This compares to a duration of action
of 8 to 12 hours for orally ingested LSD and 10 to 12 hours for mescaline, as
described by Shulgin and Shulgin (1991).
Clinical experience
2C-T-2 has not undergone any clinical or pre-clinical evaluation studies. The majority
of data is based on self-reporting by users.
Studies on street users
There have been two studies on 2C-T-2 use (Stolaroff and Wells, 1993; Murple,
2001). Stolaroff and Wells chose subjects who had ‘stable personalities’ and had
‘had no previous experience’ of the drugs tested (however, the majority of users had
used psychedelic drugs). The 63 subjects were divided into three groups: one group
of seven were given MDMA, a group of eight were given 2C-T-7 and the remainder
were given 2C-T-2. The drug doses were decided by the individuals (for 2C-T-2,
between 10 and 30 mg) and were administered in the morning on an empty
stomach, with supplementary doses after two hours if requested (11 of the 2C-T-2
users requested supplementary doses). Subjects were requested to complete a
questionnaire within a few days of the experiment. Participants were aged between
18 and 67 (the people in the 2C-T-2 group were also between 18 and 67). The
following subjective responses were evaluated: visual activity, clarity of thought, flow
of insights, increased sense of a higher meaning, feeling of wellbeing and improved
communication, energy levels and overall functioning. In general, the 2C-T-2 sample
size was larger than for the other drugs evaluated, but, overall, 2C-T-2 was found to
produce similar effects to those of 2C-T-7, though shorter and less intense/euphoric.
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The study by Murple (2001) involved collating information from 43 respondents in an
Internet-based survey presented on the Erowid website (2001). Of the respondents,
90.7 % were male and 9.3 % were female, with an age range of 16 to 47 (average
age 27). Many of the users reported pre-existing medical conditions ranging from
asthma to bipolar disorder. Data on the route of administration and dose are
presented above. However, doses of between 2.5 and 40 mg of 2C-T-2 for both oral
and intranasal administration have been reported, which may indicate that
insufflation of 2C-T-2 represents a lower risk than insufflation of 2C-T-7. Respondents
reported having used 2C-T-2 an average of 3.69 times, but with a variable frequency
of use. Of all the users, 55.8 % indicated they would be willing to use 2C-T-2 again
at the same dose, 25.6 % indicated they would like to take a higher dose and 7.0 %
reported they would not wish to use it again (of these, six individuals cited non-
specific side-effects as the reason). A number of specific comments are presented on
the website, but many users reported experiencing strong visual effects, emotional
responses similar to MDMA and some negative psychedelic mental effects (anxiety,
paranoia, panic attacks). Adverse effects such as nausea, muscle tension and
vomiting have been reported in other studies (as descibed in the ‘Toxicology’ section
above).
Overall, subjective user reports indicate that 2C-T-2 produces various psychedelic
effects (generally comparable to other hallucinogens such as mescaline, LSD and 
2C-B) along with nausea, muscle tension, vomiting and sometimes ‘negative’ mental
effects (e.g. anxiety). The effects are typically described as being less intense than
with 2C-T-7.
Dependence potential in humans
Tolerance
No specific research has been conducted on 2C-T-2. Based on anecdotal user reports,
the occurrence of tolerance to the effects of 2C-T-2 appears to be variable (Murple,
2001). If tolerance does occur, it is possible that cross-tolerance may occur between
other related psychedelic phenethylamines such as 2C-T-7, 2C-B and mescaline.
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Dependence potential
No specific research has been conducted on 2C-T-2. Although the specific
pharmacology of 2C-T-2 is unknown, speculative comparison with related compounds
suggests that it is unlikely to produce physical dependence or addiction. However,
without specific studies, definitive conclusions cannot be drawn.
Psychological risk assessment (cognition, mood and mental functioning)
Acute and chronic effects
There are no published data on the specific psychological effects, acute or chronic, of
2C-T-2. As described in the pharmacological report, anecdotal reports from users
describe various subjective psychological effects that occur with 2C-T-2 use.
In a study by Stolaroff and Wells (1993), 75 % of users reported enhanced clarity of
thought and 5 % described a loss of clarity; 77.5 % of users reported an improvement
in the ‘flow of insights’, with only 2.5 % reporting that this worsened; 82.5 %
described an increase in the perception of a higher meaning (compared to 62.5 % for
2C-T-7); 80 % of users reported an improvement in their sense of wellbeing
(compared to 100 % for MDMA). Finally, 62.5 % of users also described an
improvement in communication skills and 17.5 % reported a deterioration in such
skills.
Reports from 43 users collated by Murple (2001) mentioned various feelings of
wellbeing and mental clarity a day after ingestion, whereas some users described
being mentally drained and emotionally disturbed. When questioned about the
possible long-term effects, 46.5 % of users failed to answer, 18.6 % felt they had
benefited psychologically, no users felt they had been psychologically harmed and
34.9 % felt there were no long-term psychological effects. However, such responses
are purely speculative in terms of the potential chronic effects of 2C-T-2.
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Conclusions
• 2C-T-2 is a synthetic drug which was first synthesised in 1981 by Shulgin.
• Seized/available material includes white powder or white tablets.
• 2C-T-2 has no licensed therapeutic or industrial use.
• 2C-T-2 is a potential 5-HT2C, 5-HT2A, 5-HT1 and 1-adrenergic receptor agonist.
• Users report hallucinogenic/visual effects similar to 2C-B, LSD and mescaline, and
feelings of empathy similar to MDMA. Other effects reported are nausea, muscle
tension, vomiting, anxiety and some confusion/disorientation.
• Self-reporting users have only mentioned oral ingestion and insufflation (snorting) of
2C-T-2.
• Due to the lack of specific scientific evidence, acute or chronic toxicity of 2C-T-2 has
not been confirmed in humans, but toxic effects cannot be excluded.
• There have been no reported cases of fatal or non-fatal intoxication.
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Review of the pharmacotoxicological data on
2C-T-7 (13)
Very limited data for 2C-T-7 have been published in peer-reviewed scientific journals.
The following information includes studies involving structurally related compounds
and user-based evidence (Information Classification IV, EMCDDA, 1999). Studies are
ongoing to obtain further scientific data on this compound.
Chemical and pharmaceutical information
Chemical description
The chemical structure of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) is
shown below (Figure 1). The abbreviation ‘2C-T-7’ is derived from the nomenclature
according to Shulgin and Shulgin (1991), and, although this compound has more
carbons than 2C-T-2, the ‘-7’ part of the abbreviation has no structural significance
but simply refers to the historical order of study/discovery (Pihkal No 43). Other
chemical names are rearrangements of the name shown above (such as 4-propylthio-
2,5-dimethoxy-phenethylamine, or PT-DM-PEA).
Chemical structure of 2C-T-7
Molecular formula: C13H21NO2S
Molecular weight: 255.37
There is no chemical abstracts registration (CAS) number for 2C-T-7. 2C-T-7 base is
an oil, whereas 2C-T-7 hydrochloride is a white crystalline solid.
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(13) This report was written by S. P. Elliott of the Regional Laboratory for Toxicology (City Hospital, Birmingham, United
Kingdom) for the risk assessment meeting on 2C-T-7 held in Lisbon on 31 March and 1 April 2003. Help and
information was provided by: S. Ahlstrom, D. Corrigan, C. Furnari, J. Idanpaa-Heikkila, M. Mallaret, C. Poethko-Muller,
J-P. Tassin, A. Wallon, R. Wennig, L. Westberg. The report was commissioned by the EMCDDA as a background paper
for the risk assessment of the compound 2C-T-7. The report follows the structure of Annexes A and B of the risk
assessment guidelines developed by the Scientific Committee of the EMCDDA.
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Methods of synthesis
It is thought that 2C-T-7 was first synthesised in 1986 by Shulgin (Hardison, 2000;
Erowid, 2001). A synthesis protocol was later described in Pihkal based on initial use
of 1,4-dimethoxybenzene to produce a preliminary precursor, 2,5-
dimethoxythiophenol (Shulgin and Shulgin, 1991). Shulgin and Shulgin describe the
latter compound as a ‘valuable precursor to all members of the 2C-T family’ and this
is now available commercially (Poortman, 1999). The method is extensive, requiring
specialist equipment and an appropriate environment. There is no information about
the exact method of synthesis used by clandestine laboratories.
Identification
2C-T-7 exhibits a slow/weak ‘salmon orange’ (pink, orange-red) colour using the
Marquis reagent assay (Erowid, 2000; LTG, 2001; Zimmerman, 2001). A change
from dark orange to a dark purplish orange was observed using Mecke’s reagent and
a cherry-red colour was observed using sodium nitroprusside reagent (Zimmerman,
2001). There is some information regarding the analytical profile of 2C-T-7 using
common methods such as gas chromatography with mass spectrometry (GC-MS), or
nitrogen-phosphorus detection (GC-NPD), or high performance liquid
chromatography with diode-array detection (HPLC-DAD). Curtis et al. (2001) have
extracted and identified 2C-T-7 in biological fluids based on GC-NPD with GC-MS
confirmatory analysis. Electron impact (EI) mass spectral data have indicated major
abundant ions of 226, 183, 255 (molecular ion), 153 and 169 (in order of
abundance) (LTG, 2001; Zimmerman, 2001). HPLC-DAD data have shown UV
maxima of 206, 253 and 304 nm with a UV spectrum different to that of other
phenethylamines, including MDMA, amphetamine and 2C-B (Elliott, 2000). Nuclear
magnetic resonance (NMR) and Fourier transform infrared spectroscopy (FTIR) data
have also been described (Zimmerman, 2001). 2C-T-7 would not be detected by
commonly used immunoassay procedures for the preliminary identification of
amphetamines in urine (particularly based on monoclonal antibodies), unless it were
present at unusually high concentrations (Elliott, 2001; LTG, 2001).
Legitimate uses of 2C-T-7
There are no known licensed therapeutic uses for 2C-T-7. However, there is some
information indicating its use in ‘psychedelic therapy’ (Shulgin and Shulgin, 1991;
Stolaroff and Wells, 1993; Murple, 2001a).
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Pharmaceutical form
2C-T-7 is typically available in powder or tablet form, but it may also be found in
capsules or liquid form. It has various ‘street names’, including ‘T-seven’, ‘Beautiful’,
‘Lucky seven’, ‘Seven-up’, ‘Seventh heaven’, ‘Red raspberry’, ‘Tweety bird mescaline’
and ‘Tripstasy’ (Murple, 2001a). Tablets referred to as ‘Green fish’ and ‘Number
seven’ allegedly contained 2C-T-7, but this could not be confirmed by specific analysis
(Murple, 2001a). 2C-T-7 may also have been sold as ketamine. However, as with the
majority of information regarding the illicit market, evidence is anecdotal at best.
Between 1999 and 2001, 2C-T-7 was available commercially as ‘Blue mystic’ via
Dutch smartshops; the presence of the compound was confirmed by laboratory
analysis (Niesink, 2000) and was referred to as PT-DM-PEA on the packaging
(originally 7.5 mg, then reformulated to 10 mg). Such tablets are blue in colour, with
a ‘Yin-yang’ logo, and are approximately 7.4 x 4.8 mm, weighing 265 mg (LTG,
2001).
The purchase price varies but is largely comparable to other phenethylamine
derivatives such as MDMA (typically EUR 5 to 20) (Erowid, 2002).
Routes of administration and dosage
As 2C-T-7 is obtained in powder or tablet form, the primary route of administration is
oral, but insufflation (snorting) is also frequently mentioned in user reports (Murple,
2001a). Less common routes of administration include smoking and rectal,
intravenous or intramuscular administration (Murple, 2001a). In the Murple survey of
423 self-reporting 2C-T-7 users, respondents indicated that their usual routes of
administration were: oral (68.1 %), insufflation (27.9 %), smoking (2.8 %), rectal
(1.2 %) and intravenous/intramuscular (0 %).
Original studies by Shulgin and Shulgin (1991) involved oral administration of 2C-T-7
doses of 20 to 30 mg but indicated that around 10 mg may be sufficient for some
users. This is compared to a Pihkal ‘recommended’ dose of 80 to 150 mg for MDMA,
178 to 256 mg for mescaline (hydrochloride), 12 to 24 mg for 2C-B, 60 to 100 mg
for 2C-T, 10 to 30 mg for 2C-T-7, 1 to 3 mg for DOB and 3 to 10 mg for DOM
(Shulgin and Shulgin, 1991) and a Tihkal ‘recommended’ dose of 0.06 to 0.2 mg for
LSD (Shulgin and Shulgin, 1997). Respondents in a user survey mentioned oral doses
of 1 to 125 mg (average 27 mg), intranasal doses of 0.5 to 50 mg (average 15 mg),
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rectal doses of 7 to 33 mg (average 15 mg) and smoking doses of 1 to 40 mg
(average 12 mg) and the few respondents using the intravenous/intramuscular route
mentioned doses of 1 to 3 mg (Murple, 2001a). The wide range of doses mentioned
(particularly for oral administration) and some of the respondents’ comments
suggested that there may be some individual sensitivity to 2C-T-7. It should be noted,
however, that the accuracy of the comments collated by Murple is dependent on user
honesty and accurate weighing of the compound or knowledge of the actual
content/weight of the tablet/powder’s constituents.
Toxicology and pharmacology in animals and humans
No data for 2C-T-7 have been published in peer-reviewed scientific journals. The
following information is based on speculative comparison with partially related
compounds such as 2C-B (which is based on phenethylamine) and DOB (which is
based on amphetamine), both involving bromine as opposed to sulphur. It is
inappropriate to compare data derived from MDMA, PMA and 4-MTA studies, due to
the absence of 2,5-dimethoxy substituent groups in such compounds.
Neuropharmacology
No specific research has been conducted using 2C-T-7. Studies by Lobos et al. (1992)
involving a bromine-substituted analogue, 2C-B (4-bromo-2,5-
dimethoxyphenethylamine), have shown it to be a partial agonist for 5-HT2 (5-HT2A
and 5-HT2C) serotonergic receptors and 1-adrenergic receptors. At 10-6M, 2C-B also
acted as a competitive 5-HT antagonist, but, at higher concentrations (2.8 x 10-5M), it
acted as a non-competitive 5-HT antagonist (Lobos et al., 1992). In addition, Glennon
et al. (1988) found that DOB (4-bromo-2,5-dimethoxyamphetamine) had a high
affinity for 5-HT2 receptors, whereas 2C-B was also found to have significant affinity
for 5-HT1A, 5-HT1B and 5-HT1C receptors and thus was deemed to be less selective than
its amphetamine-based analogue, DOB. Therefore, as 2C-T-7 is phenethylamine
based, it is possible it may have serotonergic receptor affinity similar to 2C-B (i.e.
binding to 5-HT2 and, to some degree, 5-HT1 receptors). Researchers have already
provided evidence of the involvement of 5-HT2 serotonergic receptors (in particular 
5-HT2A) in the action of hallucinogenic agents (Glennon et al., 1984). It is
conceivable, therefore, that the apparent hallucinogenic effects of 2C-T-7 may be
related to similar receptor affinities. However, such conjecture is only based on limited
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information on related compounds and further specific studies of 2C-T-7 are required
before definitive conclusions can be drawn.
Neuroendocrinology
No specific research has been conducted using 2C-T-7. Serotonin agonists stimulate
hypothalamic neurons involved in ACTH and cortisol secretion (Fuller, 1981), in
addition to stimulating growth hormone and prolactin secretion (as evidenced by
mescaline and DOM) (Meltzer et al., 1978, 1981; Demisch and Neubauer, 1979). It
is possible, therefore, that 2C-T-7 may produce similar effects on hormonal secretion.
Cardiovascular and thermoregulatory responses
No specific research has been conducted using 2C-T-7. Only subjective evidence is
available from user surveys, which indicates varying observations for these clinical
features. User comments compiled by Murple (2001b) indicated that 21.8 %
experienced tachycardia and 5.9 % experienced hypertension (both largely route
independent). It is doubtful, however, that users had access to blood pressure and
heart rate monitors for medical confirmation of these symptoms. Headaches were
noted by 31.9 % of users, indicating possible increased blood pressure (Murple,
2001b). Tachycardia was also mentioned in the evaluation conducted by Hardison
(2000). The Murple user survey also included inconsistent observations regarding
effects on body temperature, with users feeling hot and/or cold. There did not appear
to be any obvious consistency between reports.
Toxicology
At present, there are no animal or human data concerning the general toxicity,
reproductive toxicity, neurotoxicity or the mutagenicity and carcinogenic potential of
2C-T-7.
Toxicity in animals
Shulgin and Shulgin (1991) reported on studies on mice involving intraperitoneal
(i.p.) administration of DOB and found the LD50 to be between 100 and 125 mg/kg.
Administration of 50 mg/kg (i.p.) resulted in twitching, 100 mg/kg produced
shaking, and mice receiving >125 mg/kg exhibited convulsions and eventually died.
No such studies have been conducted for 2C-T-7 and, due to the significant structural
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differences between DOB and 2C-T-7 (which is likely to alter the toxicity of the
respective compounds), such data are not directly comparable. In particular, Shulgin
describes 2 mg as an effective dose for DOB but suggests that 10 mg may be
required using 2C-T-7.
Toxicity in humans
As mentioned above, only subjective evidence is available from user surveys on the
apparent adverse effects and toxic symptoms of 2C-T-7. In a study of 423 self-
reporting 2C-T-7 users described by Murple (2001a), side-effects of varying degrees
were noted in approximately 85 % of users. Of these, 3 % found them to be
prolonged and severe. Intranasal administration appeared to result in a greater
number of adverse user reports than oral administration. The most common side-effect
was nausea (62.7 %), followed by headaches (31.9 %), vomiting (30.5 %),
tachycardia (21.8 %), dehydration (18.0 %; probably related to diarrhoea/vomiting
or the administration situation/environment), diarrhoea (6.2 %), hypertension (5.9 %)
and, to a smaller extent, some gastrointestinal effects, confusion or delirium (at high
doses), dizziness and muscle spasms. It should be noted that, overall, there were more
adverse effects with 2C-T-7 compared to 2C-T-2. However, the 2C-T-2 study was far
smaller (43 respondents) than the 2C-T-7 study (423 respondents). Similar adverse
symptoms were reported in a study by Stolaroff and Wells (1993), in particular
nausea, vomiting, muscle tension/spasms and some inconsistent cardiac effects.
Interactions with other drugs or medicines
Unlike other phenethylamine derivatives, including 2C-B, it appears that 2C-T-7 is not
usually present in tablets containing other phenethylamines or stimulants (De Boer et
al., 1999; Erowid, 2000). This therefore reduces the possibility of concomitant
ingestion of other drugs in such illicit preparations. However, as the pharmacology of
2C-T-7 is largely unknown, it is difficult to predict with accuracy any particular
potential drug interactions or contraindications. Winter et al. (1999) studied the acute
effects of monoamine reuptake inhibitors (SSRIs such as fluvoxamine, fluoxetine and
venlafaxine) on the stimulus effects of hallucinogens (including DOM) and observed
an additivity of effects rather than a potentiation. It is possible, therefore, that similar
effects may occur with 2C-T-7. Some user reports collated by Murple have mentioned
the concurrent use of other drugs (Murple, 2001a). Other psychedelic drugs
apparently produced synergistic effects, whereas benzodiazepines and GHB
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produced anxiolytic and sedative effects. Stimulants, including caffeine and cocaine,
appeared to be potentiated by 2C-T-7. Simultaneous use with benzylpiperazine was
reported by several users to reduce the physical side-effects, but one user reported a
tachycardia with a heart rate of over 160 bpm. There were a number of individual
comments made by users regarding single drugs, but these have not been included in
this report. Despite the concomitant use of MDMA by some users, there was no
information indicating enhanced MDMA toxicity due to direct (e.g. synergistic) or
indirect (e.g. metabolic) effects. In addition, potential adverse interaction with
monoamine oxidase inhibitors (MAOIs) has been mentioned, including in the product
insert provided with ‘Blue mystic’ (Erowid, 2000; Murple, 2001a). Murple describes
two reports of adverse reactions with deprenyl (MAO B reversible inhibitor), including
an incident observed by Shulgin. However, specific studies involving such drugs in
combination with 2C-T-7 have not been conducted, so these and the other potential
interactions described above have not been confirmed.
Non-fatal cases of 2C-T-7 intoxication in humans
As 2C-T-7 is not usually detected during routine toxicological analysis (typically due to
the lack of any reference material), the indication of use is usually based on anecdotal
or circumstantial evidence (if any information is available to the medical staff at all).
Consequently, confirmed cases of 2C-T-7 intoxication are rare, with no published
instances. The Erowid website has received a ‘handful of reports’ within a four-month
period from users reporting hospitalisation resulting from 2C-T-7 use alone (Erowid,
2001). Erowid also reported that high doses can result in prolonged effects associated
with individuals ‘wandering around ... and ... being incapable of taking care of
themselves’. The user survey responses received by Murple (2001a) from respondents
in the USA, Mexico, Finland and the Netherlands included anecdotal reports. These
reports provide some indication of the circumstances of abuse, but, due to the
voluntary nature of the evidence, the details remain anecdotal at best. A brief
synopsis follows for each case.
• USA (no date): Approximately 10 minutes following intravenous administration of
25 mg of 2C-T-7 the user became very violent, eventually having to be restrained
by the police (including the use of a pepper spray). He was taken to hospital, where
he briefly stopped breathing and then became comatose for five days, prior to
recovery and discharge.
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• USA (2000): Following intranasal administration of 25 mg of 2C-T-7 the user
vomited and became extremely confused and disorientated, resulting in emergency
admission to hospital. He was discharged the following day.
• Mexico (no date): Following oral administration of 30 mg of 2C-T-7, alcohol
ingestion and cannabis smoking, the user collapsed in the street, hit his head and
suffered convulsions. He was taken to hospital where a ‘mild heart attack’ was
diagnosed along with concussion. He was a young man who also used LSD,
psilocybin and MDMA and may have had a pre-existing heart condition.
• Finland (2000): Following intranasal administration of an estimated 10 mg of 
2C-T-7 the user vomited and subsequently fell and hit her head. She suffered
convulsions and was taken to hospital. It took more than 10 hours for the effects to
wear off for 10 other users that used the same 2C-T-7.
• Netherlands (no date): There is very little information available for this. Possible
administration of 2C-T-7 (unspecified route and dose) led to two men panicking and
becoming entangled in barbed wire. They were freed by police and taken to
hospital, where one man lapsed into a coma for a few days and later recovered.
Overall, there are no confirmed reports of 2C-T-7 administration resulting in non-fatal
intoxication. Despite the information described above, there is still very little clinical
information about the effects of 2C-T-7 following overdose. Consequently, there are
no accurate frequency or demographic data for such instances.
Fatal cases of 2C-T-7 intoxication in humans
At present (as of 2003), three deaths potentially involving 2C-T-7 have been reported
in the USA (Erowid, 2001; DEA, 2002). Of these, the presence of 2C-T-7 was
confirmed in only one case following specific toxicological analysis. No deaths have
been linked to 2C-T-7 within Europe. However, the lack of reference material on
clinical toxicology may compromise post-mortem cases. A brief synopsis of the
reported fatalities follows.
• USA (2000): Following intranasal administration of 35 mg of 2C-T-7, a 20-year-old
male began to feel cold and experienced vomiting and hallucinations. An hour after
administration, he became agitated and aggressive and suffered convulsions. About
110 minutes after administration, his companions noticed he had turned blue and
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conveyed him to hospital, during which time he stopped breathing, suffered cardiac
arrest and died (Erowid, 2001; DEA, 2002). Following toxicological analysis, an
unidentified compound in the urine was found to be 2C-T-7 (Curtis et al., 2001).
Subsequent analysis detected 2C-T-7 at concentrations of 54 g/L (micrograms per
litre) in heart blood, 100 g/L in femoral blood, less than 26 g/L in vitreous
humour, 340 ng/g in the brain and 440 g/L in the urine (Curtis et al., 2001).
• USA (2001): A 17-year-old male apparently took two MDMA tablets and possibly
also ephedrine 10 hours prior to intranasal administration of 35 mg of 2C-T-7.
Shortly after insufflation of 2C-T-7, he began vomiting, which lasted for 30 to 40
minutes. He then became disorientated and violent and was taken outside, where
he was later found unconscious in a friend’s car. He died in the car on the way to
hospital. The post-mortem specimens were not initially analysed for 2C-T-7. Some
months later, the stored blood was analysed, but the findings were ‘inconclusive’
(Erowid, 2001; DEA, 2002).
• USA (2001): Following oral ingestion of a mixture of 200 mg of MDMA and the
contents of a black capsule believed to contain 2C-T-7 (dose unknown), a 24-year-
old male became agitated and aggressive/violent. He appears to have suffered
seizures and his breathing became irregular. An ambulance was called and he was
conveyed to hospital but died shortly after admission (Erowid, 2001; DEA, 2002).
Toxicological analysis detected MDMA in the post-mortem blood. No 2C-T-7 was
detected in the gastric contents or the liver, but it was identified on the plate
believed to have been used to mix the drugs (DEA, 2002).
In conclusion, further data concerning both the circumstances of death and the
toxicological findings are required before the involvement of 2C-T-7 can be
established and accurate mortality and morbidity figures produced.
Pharmacokinetics and metabolism
No specific research has been conducted using 2C-T-7. However, metabolic studies
using 2C-B have been conducted on rats and by analysis of human urine (De Boer et
al., 1998; Kanamori et al., 2002). Kanamori et al. (2002) identified two pathways in
the rat involving (a) initial deamination followed by reduction or oxidation; and (b) 2-
or 5-position O-desmethylation followed by amino acetylation. De Boer et al. (1998)
identified the unchanged parent compound (i.e. 2C-B) in addition to 4-bromo-2,5-
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dimethoxyphenylacetic acid, 4-bromo-2,5-dimethoxybenzoic acid and 4-bromo-5-
hydroxy-2-methoxyphenethylamine in the urine of 2C-B users. It is likely that
metabolism of 2C-T-7 may proceed via similar pathways, probably involving
oxidative deamination (I, II) and O-desmethylation of the aromatic methoxy groups
(III) in addition to excretion of unchanged drug (the possibility of species-dependent
metabolism notwithstanding). This would lead to the corresponding compounds:
I = 2,5-dimethoxy-4-propylthiophenylacetic acid
II = 2,5-dimethoxy-4-propylthiobenzoic acid
III = 4-propylthio-5-hydroxy-2-methoxyphenethylamine
However, additional metabolic reactions are a possibility, particularly involving the
propylthio moiety at the 4-position or (as observed in rats by Kanamori et al., 2002)
potential N-acetylation.
Anecdotal evidence from users indicates an onset of action of one to two and a half
hours, particularly if taken on an empty stomach, with effects lasting up to 15 hours
(Hardison, 2000; Erowid, 2001). However, these data typically refer to oral ingestion
and user comments indicate more rapid onset and shorter duration of effects
following insufflation (Murple, 2001b). This compares to a duration of action of
8 to 12 hours for orally ingested LSD and 10 to 12 hours for mescaline (Shulgin and
Shulgin, 1991).
Clinical experience
2C-T-7 has not undergone any clinical or pre-clinical evaluation studies. The majority
of data is based on self-reporting by users.
Studies on street users
There have been three studies on 2C-T-7 use (Stolaroff and Wells, 1993; Hardison,
2000; Murple, 2001a). Stolaroff and Wells chose subjects who had ‘stable
personalities’ and had ‘had no previous experience’ of the drugs tested (however, the
majority of users had used psychedelic drugs). The 63 subjects were divided into three
groups: seven were given MDMA, eight were given 2C-T-7 and the remainder were
given 2C-T-2. The drug doses were decided by the individuals (for 2C-T-7, between
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20 and 25 mg) and were administered in the morning on an empty stomach, with
supplementary doses after two hours if requested (six of the eight 2C-T-7 users
requested supplementary doses). Subjects were requested to complete a questionnaire
within a few days of the experiment. Participants were aged between 18 and 67 (the
2C-T-7 group were aged between 30 and 57). The following subjective responses
were evaluated: visual activity, clarity of thought, effects on flow of insights, increased
perception of higher meaning, a feeling of wellbeing and improved communication
skills, energy level and overall functioning. In general, the 2C-T-7 sample size was
fairly limited and so responses require further confirmation. However, overall, 2C-T-7
was found to produce similar effects to those of 2C-T-2, though longer and more
intense/euphoric.
Hardison (2000) evaluated retrospectively the subjective reports of 42 2C-T-7 users
(13 females and 29 males) aged 24 to 73. Of these, 33 reported having no previous
experience of 2C-T-7. Doses of between 25 and 45 mg were voluntarily administered
(25 to 45 mg for males and 25 to 33 mg for females). Some users had also used
cannabis (11 users), dihydrocodeine and diazepam (2), alcohol (1), cocaine (1) and
‘flower essences’ (1) at the same time as 2C-T-7. The onset of effects appeared to
range from 15 minutes to four hours (typically one to two hours) and peak
experiences occurred after one to six hours and lasted a further one to five hours, but
the total length of duration was reported to be between eight and 18 hours.
Comments relating to the users’ mindset, clarity of thought, movement and energy
levels were requested. Respondents noted various subjective responses: ‘complete and
utter bliss, incredible, cosmic and extremely grateful’, ‘general sense of wellbeing’,
‘some emotional periods, feeling sad and disorientated’ and ‘some difficulties in
focusing my thoughts, clear but disorientated’. The majority of responses were
described as being largely similar for all users. Various adverse effects were noted
(described in the section ‘Toxicology’) and these were similar to those reported in
other studies (e.g. headaches and extreme nausea).
The study by Murple (2001a) involved collating information from 423 respondents in
an Internet-based survey presented on the Erowid website (Erowid, 2001). Of
respondents, 89.4 % were male and 9.9 % were female (0.7 % not specified), with an
age range of 14 to 64 (average age 27). Many of the users reported pre-existing
medical conditions ranging from asthma to bipolar disorder. Data on the route of
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administration and dose are presented above. However, doses of 1 to 125 mg of 2C-
T-7 (particularly for oral ingestion) were reported, with lower doses (up to 50 mg)
taken via insufflation, intravenous/intramuscular administration, smoking and rectal
administration. Respondents reported having used 2C-T-7 an average of 4.78 times,
but with a variable frequency of use. Of all users, 48.0 % indicated they would be
willing to use 2C-T-7 again at the same dose, but 5.0 % reported they would not wish
to use it again (particularly intranasal users), as a number of these individuals had
experienced pain following insufflation and the effects were too intense. A large
number of specific comments are presented on the website, but many users reported
experiencing strong visual effects, emotional responses similar to MDMA, some
negative psychedelic mental effects (e.g. anxiety, paranoia, panic attacks), delirium
(at high doses), an increased sense of physical fitness and general enhancement of
the senses. As with the other studies described here, adverse effects such as
headache, nausea and vomiting were noted (described in the section ‘Toxicology’).
Overall, subjective user reports indicate that 2C-T-7 produces various psychedelic
effects (generally comparable to other hallucinogens such as mescaline, LSD and 
2C-B), along with vomiting, headaches and sometimes ‘negative’ mental effects 
(e.g. anxiety). The effects are typically described as being intense, often causing
severe disorientation/disassociation at high doses, particularly following insufflation.
Dependence potential in humans
Tolerance
No specific research has been conducted using 2C-T-7. Based on anecdotal user
reports, the occurrence of tolerance to the effects of 2C-T-7 appears to be variable
(Murple, 2001a). Some users report a definite tolerance, whilst some who have
regularly used low doses do not. The Erowid website (2001) suggests that using 
2C-T-7 two days in a row is likely to lead to a diminished experience on the second
day. If tolerance does occur, it is possible that cross-tolerance may occur between
other related psychedelic phenethylamines such as 2C-T-2, 2C-B and mescaline.
Dependence potential
No specific research has been conducted using 2C-T-7. Despite this, the Erowid
website (2001) states that 2C-T-7 is neither physically addictive nor is it likely to cause
psychological dependence. Although the specific pharmacology of 2C-T-7 is
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unknown, speculative comparison with related compounds suggests that it is unlikely
to produce physical dependence or addiction such as occurs with opiate use.
However, without specific studies, definitive conclusions cannot be drawn.
Psychological risk assessment (cognition, mood and mental functioning)
Acute and chronic effects
There are no published data on the specific psychological effects of 2C-T-7, acute or
chronic. As described in the pharmacological report, anecdotal reports from users
describe various subjective psychological effects that occur with 2C-T-7 use.
In a study by Stolaroff and Wells (1993), 87.5 % of users reported enhanced clarity
of thought and 12.5 % described diminished clarity; 50 % of users reported an
improvement in the ‘flow of insights’ and 12.5 % reported that this worsened; 62.5 %
described an increase in the perception of a higher meaning (compared to 82.5 % for
2C-T-2); 75 % of users reported an improvement in their sense of wellbeing
(compared to 100 % for MDMA). Finally, 75 % of users also described an
improvement in their communication skills, but there were no reports of 2C-T-7
impairing communication skills.
A retrospective subjective study of 2C-T-7 users by Hardison (2000) included specific
comments such as ‘extraordinary free roaming, very lucid and philosophic’, ‘complete
and utter bliss, incredible, cosmic and extremely grateful’, ‘general sense of
wellbeing, I had many insights, catharsis early on’, ‘some emotional periods, feeling
sad and disorientated’, ‘clarity of thought somewhere between MDMA and LSD’,
‘some difficulties in focusing my thoughts, clear but disorientated’, ‘I moved in an easy
coordinated manner while hiking and climbing’ and ‘clarity uncaged, crystalline
thoughts, movements like an animal, confident and energetic’.
Reports by 423 users collated by Murple (2001b) also included numerous comments.
One user in particular stated, ‘I found it to be one of the most powerful cognition
enhancers I’ve ever encountered’. Some users also mentioned experiencing feelings of
empathy similar to MDMA. After-effects included euphoria and, conversely, ‘mental
sluggishness’, including impaired memory recall, mild confusion/disorientation and
difficulty in concentrating. When questions about the possible long-term effects were
posed, 36.9 % of users failed to answer, 29.6 % felt they had benefited
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psychologically, 2.1 % felt they had been psychologically harmed and 30.0 % felt
there were no long-term psychological effects. However, such responses are purely
speculative in terms of the potential chronic effects of 2C-T-7.
Conclusions
• 2C-T-7 is a synthetic drug which was first synthesised in 1986 by Shulgin.
• Seized/available material includes powder, tablets (blue, ‘Yin-yang’ logo), capsules
or liquid preparations.
• 2C-T-7 has no licensed therapeutic or industrial use.
• 2C-T-7 is a potential 5-HT2C, 5-HT2A, 5-HT1 and 1-adrenergic receptor agonist.
• Users report hallucinogenic/visual effects (similar to 2C-B, LSD and mescaline) and
emotional/empathetic responses (similar to MDMA). Other effects reported are
nausea, headaches, vomiting, anxiety, confusion/disorientation, agitation,
aggression and violent behaviour.
• Both oral ingestion and insufflation (snorting) of 2C-T-7 have been reported.
However, self-reporting users have also mentioned rectal use and injection.
• Due to the lack of specific scientific evidence, acute or chronic toxicity of 2C-T-7 has
not been confirmed in humans, but toxic effects cannot be excluded.
• There has been one death in which the involvement of 2C-T-7 has been confirmed
in the USA; and no reported fatalities in Europe. There have been no confirmed
reports of non-fatal intoxication.
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Table 1: Comparison of pharmacotoxicological data for 2C-I, 
2C-T-2 and 2C-T-7
2C-I 2C-T-2 2C-T-7
Synthesis 2,5-dimethoxyben- 1,4- 1,4-dimethoxy-
(precursors) zaldehyde, used to dimethoxybenzene, benzene, used to 
form 2,5-dimetho- used to form 2,5- form 2,5-dimetho-
xyphenethylamine dimethoxythiophenol xythiophenol
Identification No information Marquis (red orange) Marquis (pink 
(reported GC-MS and FTIR orange)
techniques) HPLC, GC-NPD,
GC-MS, NMR
and FTIR
Form Powder, tablet Powder, tablet Powder, tablet 
(white, ‘i’ logo) and (white) (‘Blue mystic’), 
liquid capsules and
liquid
Dose
oral 15–20 mg (Pihkal) 12–25 mg (Pihkal) 10–30 mg (Pihkal)
3–25 mg (users) 5–40 mg (users) 1–125 mg (users)
insufflation No information 2.5–35 mg 0.5–50 mg 
(average 13 mg) (average 15 mg)
Route Oral Oral (83.7 %) and Oral (68.1 %), 
insufflation (16.3 %) insufflation (27.9
%), smoking (2.8
%), rectal (1.2 %)
and i.v./i.m. (0 %) 
Metabolism Oxidative Oxidative Oxidative 
(based on 2C-B deamination deamination deamination
data) O-desmethylation O-desmethylation O-desmethylation
N-acetylation N-acetylation N-acetylation
Sulphoxidation Sulphoxidation
Neuropharma- 5-HT2C, 5-HT2A and 5-HT2C, 5-HT2A, 5-HT2C, 5-HT2A,
cology serotonergic 5-HT1 serotonergic 5-HT1 serotonergic
receptors and 1-adrenergic and 1-adrenergic
(published data) receptors (based on receptors (based 
2C-B and DOB data) on 2C-B and DOB
data)
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2C-I 2C-T-2 2C-T-7
Cardiac effects No information Tachycardia Tachycardia 
(16.3 %) (21.8 %)
Hypertension Hypertension 
(2.3 %) (5.9 %)
Thermoregulatory 
response No information Inconclusive Inconclusive
Toxicity Delayed effects 1. Nausea (60.5 %) 1. Nausea 
(in humans) (possible additional 2. Muscle tension (62.7 %)
dosage) (32.6 %) 2. Headaches 
No adverse effects 3. Vomiting (23.3 %) (31.9 %)
reported 4. Diarrhoea 3. Vomiting 
(18.6 %) (30.5 %)
5. Tachycardia/ 4. Tachycardia 
dehydration (16 %) (21.8 %)
5. Dehydration
(18 %)
Interactions SSRIs: additive SSRIs: additive SSRIs: additive 
effect with DOM effect with DOM effect with DOM
Stimulants: Stimulants: 
potentiated potentiated
Psychedelics: Psychedelics: 
syngergistic syngergistic
Sedatives: no Sedatives: no 
potentiation/synergy potientiation/
MAOIs: inconclusive synergy
MAOIs:
inconclusive
Non-fatal cases No reported cases No reported cases Violence, 
(reported agitation,
effects/toxicity) vomiting,
confusion,
disorientation,
coma
Fatal cases No reported cases No reported cases Violence, 
(reported agitation,
effects/toxicity) vomiting,
convulsions,
coma, respiratory
depression
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2C-I 2C-T-2 2C-T-7
Onset (oral) Initial effects 1 to 2 1 to 2 hours 1 to 2.5 hours
hours, but some 
users report very 
slow initial effects 
or delayed peak 
effects
Duration (oral) Up to 10 hours Up to 6 to 8 hours Up to 15 hours
Effects Hallucinogenic/ Hallucinogenic/ Hallucinogenic/
visual effects visual effects visual effects
Effects similar to or Effects less intense Effects more 
less intense than and shorter than intense and 
2C-B 2C-T-7 prolonged than 
Strong stimulant Emotional effects/ 2C-T-2
Emotional effects/ feelings of empathy Emotional 
feelings of empathy Anxiety effects/feelings of
empathy
Anxiety
Dependence/ No information Inconclusive Inconclusive
Tolerance
Psychological Improved clarity of Improved clarity of Improved clarity 
effects (7) thought thought (75 %) of thought 
Little/no Impaired clarity of (87.5 %)
psychological thought (5 %) Impaired clarity of 
effects Increased thought (12.5 %)
Feelings of empathy perception (82.5 %) Increased 
Increased feeling of perception 
wellbeing (80 %) (62.5 %)
Improved powers of Increased feeling 
communication of wellbeing 
(62.5 %) (75 %)
Psychological Improved powers 
benefit (18.6 %) of communication 
Feelings of empathy (75 %)
Psychological
benefit (29.6 %)
Feelings of
empathy
Confusion/
disorientation
Data in italics are based on uncontrolled, subjective, self-reporting user studies/reports (EMCDDA, Information Classification IV).
Percentage values relate to the survey findings of Murple (2001).
(7) Subjective psychological effects for 2C-T-2 and 2C-T-7 are based on a user survey by Murple (2001).
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Chapter 4
Sociological and criminological evidence and
public health risks of 2C-I, 2C-T-2 and 2C-T-7
Introduction
This chapter summarises the relevant data required by technical annexes C and D of
the guidelines for the risk assessment of new synthetic drugs. In the absence of
systematic studies of the use of 2C-I, 2C-T-2 and 2C-T-7, the evidence for this report is
based on limited information collected from:
1. The Reitox national focal points in the 15 EU Member States
2. Europol’s contribution to the risk assessment of 2C-I, 2C-T-2 and 2C-T-7
3. Published research literature
4. Telephone interviews with key experts in the field of drugs research
5. The Internet (English-language searches) 
6. Youth media (English-language searches)
7. EMCDDA publications
8. DEA documents
The numbers in the list above are used in this chapter, in square brackets, to code
general sources of information. Specific published references are provided at the end
of the book.
Sociological and criminological evidence 
Social consequences for the user
There is no evidence regarding the social consequences of use of 2C-I, 2C-T-2 and
2C-T-7 or the effects on the social behaviour of users. As with all illicit drug use, lack
of scientific and objective information may contribute to harm. Firstly, inaccurate
media coverage and overestimates of use may promote diffusion by encouraging
young people to try the substance. Secondly, official dissemination of inaccurate
information in order to prevent drug use by exaggerating the risks may be
counterproductive, as this may result in official sources losing credibility (Farrell,
1989; ESPAD, 1995; EMCDDA, 1999).
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Wholesale production and distribution
Law enforcement agencies from all 15 Member States reported to Europol that there is
no information available that would suggest large-scale production or distribution of
and/or trafficking in 2C-I, 2C-T-2 or 2C-T-7 or that organised crime has a role in
these activities. Germany reported incidental, small-scale production, in 1999, of 
2C-I, 2C-T-2 and 2C-T-7 in kitchen-type facilities and Sweden reported small-scale
production of 2C-I. Belgium and Italy reported that the main reason for their lack of
information is the fact that the substance is not controlled in those countries and,
therefore, no records are being kept within the law-enforcement system.
Member States’ law enforcement agencies had no record of violence in connection
with the production and distribution of, and trafficking in, 2C-I, 2C-T-2 or 2C-T-7. No
reliable data are available on the extent of money-laundering in relation to such
activities.
Public health risks: epidemiological evidence
Availability and quality of product on the market
Information based on early-warning databases suggests that 2C-I, 2C-T-2 and 2C-T-7
are very rare. Research on ecstasy use among recreational drug users in dance and
nightlife settings shows that friends are the most usual source for obtaining illicit drugs
but they are also available through retail dealers and dealer users (McElrath and
McEvoy, 1999; Mixmag study; EMCDDA, 1997).
From 1997, 2C-T-2 was sold in so-called ‘smartshops’ (1) in the Netherlands: in 1998,
Conscious Dreams began to market 2C-T-2, whilst DeSjamaan (2) were independently
obtaining and selling 2C-T-2.
In 1998 a smartshop in Sweden was selling 2C-T-2. However, smartshops stopped
selling 2C-T-2 as a result of controls introduced in April 1999 in the Netherlands and
Sweden (Murple, 2001) [1]. Since then, there has been no evidence that it has
become a black market drug. A reason for this may be that it is more difficult for
underground laboratories to manufacture 2C-T-2 than other drugs for which there is
(1) Smartshops usually sell various herbal drugs, nutritional supplements, etc.
(2) ‘Conscious Dreams’ and DeSjamaan are names for smartshops.
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more demand. An Internet search using the Google search engine in March 2003 did
not find online sales of 2C-T-2.
From 1999, 2C-T-7 was sold in smartshops in the Netherlands. In early 2000,
DeSjamaan Internet suppliers began selling 2C-T-7 under the trade name ‘Blue
Mystic’; this stopped in May 2001. According to the Amsterdam Antennae project,
2C-T-7 has not been available in Amsterdam for the past two years [1]. An Internet
search using Google in March 2003 did not find online sales of 2C-T-7. 
Reports from the Netherlands [1] indicate that white tablets containing 2C-T-2 were
sold as 2C-T-7 in 1997. In August 2002, white tablets containing 2C-T-2 were sold as
‘mescaline’ in France. In 2000, some Blue Mystic tablets contained a small amount of
2C-B [1]. 
The total amount of 2C-I, 2C-T-2 and 2C-T-7 seized in the Member States is very
small when compared to ecstasy seizures in the European Union (more than 15
million tablets annually in recent years). Denmark, Germany, Sweden and the UK
reported seizures of 2C-I (the German and Swedish seizures related to the seized
kitchen-type facilities mentioned above). Denmark, Germany, France, Finland and
Sweden reported small seizures of 2C-T-2 (the German seizure related to the seized
kitchen-type facility). Denmark reported a case of international trafficking of 2C-T-2
through the mail system; the drug originated in the Netherlands. Germany, France,
Finland and Sweden reported seizures of 2C-T-7, which were small, both in terms of
numbers and the quantities seized. Finland reported a seizure, in 2001, of 0.06 gm
of 2C-T-7. France reported a seizure, in 2001, of three tablets of 2C-T-7. Germany
reported a seizure (from the laboratory in Brannenburg), in 1999, of 7.7 gm of 
2C-T-7, and another in Berlin, between 1996 and 1998, with no further details
available. In Sweden, one seizure of 2C-T-7 occurred in 1998, one in 1999, one in
2000 and one in 2001. In all the Swedish cases, the amounts seized were small and
occurred at street level [2].
There is little information on the (street) price of 2C-I, 2C-T-2 and 2C-T-7. Purchase
prices vary but are largely comparable to other phenethylamine derivatives. Past
Internet sales (Murple, 2001) have indicated a price of around EUR5 per tablet of 
2C-T-2 or 2C-T-7 (with variations between the different shops). In October 2003, the
UK authorities issued an alert stating that a new dance drug (2C-I) ‘may appeal to
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dealers because – unlike ecstasy, which can now sell for as little as GBP 1 each – 
2C-I pills can fetch up to GBP 10 each’ [1]. 
Knowledge, perceptions and availability of information
Availability of information on effects of product
The main information sources are Internet sites and ‘dance floor pharmacology’, an
informal network whereby information passes from friend to friend. The popularity of
websites such as www.erowid.org shows the breadth of public interest in drugs. In
general, news posted on these sites is acknowledged to be so far ahead of the curve
and so readily available that official regulators use the sites to keep abreast of new
drug trends [1]. Despite the prevalence of publications warning of the potential harm
associated with using health information from the Internet, a systematic search of
peer-reviewed literature found that there were few instances of reported harm (Crocco
et al., 2000). This may be due to an actual low risk for harm associated with the use
of information available on the Internet, or to under-reporting of cases, or to bias.
Level of awareness of product, effects and perceptions among drug
consumers
There is a general absence of knowledge about 2C-I, 2C-T-2 and 2C-T-7, even
among clubbers with comparatively high prevalence of illicit drug consumption
(Mixmag study), with the exception of a very small esoteric subgroup of experimenters
who may use mescaline, DOB or 2C-B for experiencing a wider range of effects
(Schifano and Martinotti, in preparation). 2C-I has often been seized in tablet form
with an ‘I’ logo which may be to signify to users that it is not ecstasy (MDMA).
Due to a lack of peer-reviewed human research studies, the level of knowledge
among consumers, as demonstrated on the Internet, appears to be more
comprehensive than it is among the general scientific community. However,
perceptions among consumers about the contents of products sold as 2C-I, 2C-T-2
and 2C-T-7 are usually based on the information provided by suppliers and on the
typical beliefs of consumers. In the absence of accurate and regulated chemical
analysis of the contents, objective scientific knowledge remains extremely limited.
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Prevalence and patterns of use
Extent, frequency and routes of use
No reliable evidence exists on the extent and frequency of use of 2C-I, 2C-T-2 and
2C-T-7.
In the Netherlands, targeted surveys conducted by the Amsterdam Antennae project
in different settings found lifetime prevalence of 2C-T-2 use of around 2 %, compared
to over 50 % for ecstasy (1). An Internet survey of 2C-T-2 users obtained 43 valid
responses from people who had taken 2C-T-2. However, their countries of residence
are unknown, although many were probably from the USA (Murple, 2001). The same
Internet survey showed use of between 1 and 20 times, with 3.69 the average
number of times. Doses ranged from 5 mg to 40 mg, with the average being 21 mg.
Respondents in neither of the studies are representative of the general population.
In the Netherlands, targeted surveys conducted by the Amsterdam Antennae project in
different settings found lifetime prevalence of 2C-T-7 to be less than 1 %, compared to
over 50 % for ecstasy [1]. In the UK, a dance music magazine survey of nearly 500
respondents in 2002 found that none of those surveyed had ever tried 2C-T-7 [4]. An
Internet survey of 2C-T-7 users obtained 423 valid responses from people who had
taken 2C-T-7. However, their countries of residence are unknown, although many
were probably from the USA (Murple, 2001). In the same survey, use ranged from 
1 to 200 times with 4.78 the average number of times. Doses ranged from 1 mg to
125 mg with the average being 27 mg. The reported routes of administration were
oral (69 %) and by insufflation (28 %). However, very low levels of use by smoking,
rectal insertion and injecting were also reported (Murple, 2001). As above, the
respondents in the studies are not representative of the general population.
The participants in the abovementioned Internet surveys and in newsgroups report a
number of combinations of 2C-T-2 use with other drugs, and the 2C-T-7 users
reported an extensive range of combinations with other drugs (Murple, 2001). The
main purpose of using a combination of drugs is to counteract unwanted side-effects
or to enhance the desired effects.
There are no scientific reports on 2C-I use in combination with other drugs. However,
on one Internet forum users describe a number of combinations, most frequently with
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the related compounds LSD and cannabis. As 2C-I is obtained in the form of a
powder or tablet, the primary route of administration seems to be oral. Insufflation
(snorting) and other routes (e.g. intravenous administration) associated with 2C-T-2
and 2C-T-7 use (Murple, 2001) are not mentioned in 2C-I user reports (Erowid
2001–03).
Geographical distribution of use
There is some limited evidence for use of 2C-I, 2C-T-2 and 2C-T-7 within the
European Union. 2C-I has been identified in Denmark, Spain, Sweden and the United
Kingdom. 2C-T-2 has been identified in Denmark, Germany, France, the Netherlands
and Sweden. 2C-T-7 has been identified in Germany, France, the Netherlands,
Finland, Sweden and the UK [1, 2]. Internet research indicates that Japanese,
German and Dutch speakers show particular interest in 2C-T drugs (Schifano and
Martinotti, in preparation).
Trends in prevalence and patterns of use
Population surveys of young adults in the EU show that lifetime prevalence of
hallucinogenic substances, most commonly ‘magic mushrooms’, ranges from 1 % in
Finland to 12 % in the UK. School surveys of 15- to 16-year-olds show that, in the
EU, an average of 2 % of this age group have lifetime experience of LSD or other
hallucinogens, compared to 10 % in the USA (ESPAD, 1999; EMCDDA, 2002). 
According to various reports, 2C-T-2 is less available now than it was in 1999 [1, 2].
It seems to be relatively obscure and the perception remains that it is seen as an
inferior version of 2C-T-7. 2C-T-7 is also less available now than in 1999 [1, 2]; the
people looking for new experiences may have moved on to other products [4]. The
author of the Internet survey cited above suggests that the effects of 2C-T-7 are erratic
and highly dose-sensitive, making it unlikely to become very popular (Murple, 2001).  
Research has shown that, in general, people tend to use drugs as long as the positive
factors outweigh the negative. Epidemiological evidence suggests that trends in the
use of hallucinogens such as LSD and magic mushrooms are self-limiting. Two major
factors, which affect trends, are availability and the reliability of pleasant experiences.
It has been suggested that the ease with which a drug can be made and its effects are
more significant for illicit drug consumers than its illegality (McElrath and McEvoy,
1999).
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Characteristics and behaviour of users
There is little evidence about the age, gender or social status of users or about the risk
behaviours associated with use. Survey evidence from the Internet suggests that males
are more likely to use 2C-T-2 and 2C-T-7 than females (91 % of 2C-T-2 respondents
and 89 % of 2C-T-7 respondents were male). The age of people who have tried 
2C-T-2 ranges from 16 to 47 years and for 2C-T-7 from 14 to 64 years (Murple,
2001).
Special concerns relate to lack of knowledge about the contents of the drugs and
about the specific harmful effects of 2C-T-2 and 2C-T-7 use, either alone or combined
with other drugs. The group of young people who are particularly vulnerable are
those who are at high risk for a range of problems (Parker and Egginton, 2002). 
2C-I, 2C-T-2 and 2C-T-7 are, however, used by a small group of people, often
referred to as ‘psychonauts’, who have a pseudo-scientific interest in experimenting
with hallucinogenic substances. There appears to be a trend among a small but
significant minority of users towards broadening their repertoire of drug experiences,
involving a wider range of drugs and combinations. Following the publication of
Shulgin and Perry’s (2003) new book on plant isoquinolines, a trend in experimenting
with such substances might follow.
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Joint action
of 16 June 1997
adopted by the Council on the basis of Article K.3 of the Treaty on European Union,
concerning the information exchange, risk assessment and the control of new synthetic
drugs (97/396/JHA)
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on European Union, in particular Article K.3(2)(b)
thereof,
Having regard to the initiative of the Netherlands,
NOTING that the Dublin European Council welcomed the progress report on drugs on
13 and 14 December 1996 and endorsed the action proposed in that report,
including the proposal to tackle the problem of synthetic drugs at three levels, namely,
through legislation, practical cooperation against production and trafficking and
international cooperation,
REFERRING to the Joint Action 96/750/JHA of 17 December 1996, adopted by the
Council on the basis of Article K.3 of the Treaty on European Union, concerning the
approximation of the laws and practices of the Member States of the European Union
to combat drug addiction and to prevent and combat illegal drug trafficking (1),
REFERRING in particular to Article 5 of the said joint action, which provides that the
Member States shall endeavour to draft convergent legislation to the extent necessary
to make up legal ground or fill legal vacuums as regards synthetic drugs. In particular
they shall promote the establishment of a rapid information system to enable such
drugs to be identified as substances liable to be prohibited as soon as they appear
anywhere in a Member State,
(1) OJ L 342, 31.12.1996, p. 6.
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CONSIDERING that the particular dangers inherent in the development of synthetic
drugs require rapid action by the Member States,
CONSIDERING that when new synthetic drugs are not brought within the scope of
criminal law in all Member States, problems may arise in the international
cooperation between the judicial authorities and law enforcement agencies of the
Member States owing to the fact that the offence or offences in question are not
punishable under the laws of both the requesting and the requested State,
CONSIDERING that from an inventory drawn up since the adoption of the said joint
action it can be concluded that new synthetic drugs have appeared within the
Member States,
CONSIDERING that common action can be taken only on the basis of reliable
information on the emergence of new synthetic drugs and the results of expert
assessment of the risks caused by the use of the new synthetic drugs and implications
of submitting such drugs under control,
CONSIDERING that it is therefore necessary to set up a common mechanism
permitting expeditious action, in taking necessary measures or introducing controls on
new synthetic drugs, on the basis of a rapid exchange of information on new
synthetic drugs emerging in the Member States and the common assessment of the
risks thereof,
WITHOUT PREJUDICE to the powers of the European Community,
HAS ADOPTED THIS JOINT ACTION:
Article 1
Purpose
This joint action aims at the creation of a mechanism for rapid exchange of
information on new synthetic drugs and the assessment of their risks in order to permit
Joint action
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the application of the measures of control on psychotropic substances, applicable in
the Member States, equally to new synthetic drugs. This mechanism will be jointly
implemented in accordance with the procedures established hereunder.
Article 2
Scope
This joint action concerns new synthetic drugs which are not currently listed in any of
the schedules to the 1971 United Nations Convention on Psychotropic Substances,
and which pose a comparable serious threat to public health as the substances listed
in Schedules I or II thereto and which have a limited therapeutic value. It relates to
end-products, as distinct from precursors in respect of which Council Regulation (EEC)
No 3677/90 of 13 December 1990 laying down measures to be taken to discourage
the diversion of certain substances to the illicit manufacture of narcotic drugs and
psychotropic substances (2) and Council Directive 92/109/EEC of 14 December 1992
on the manufacture and the placing on the market of certain substances used in the
illicit manufacture of narcotic drugs and psychotropic substances (3) provide for a
Community regime.
Article 3
Exchange of information
1. Each Member State shall ensure that its Europol national unit and its representative
in the Reitox network provide information on the production, traffic and use of new
synthetic drugs to the Europol Drugs Unit (EDU) of the European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA), taking into account the respective
mandates of these two bodies. The EDU and the EMCDDA shall collect the
information received and communicate this information in an appropriate manner
(2) OJ L 357, 20.12.1990, p. 1. Regulation as last amended by Commission Regulation (EEC) No 3769/92 (OJ L 383,
29.12.1992, p. 17).
(3) OJ L 370, 19.12.1992, p. 76. Directive as amended by Directive 93/46/EEC (OJ L 159, 1.7.1993, p. 134).
134
Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs
immediately to each other and to the Europol national units and the representatives
of the Reitox network of the Member States, to the Commission and the European
Agency for the Evaluation of Medicinal Products.
2. The information referred to in paragraph 1 shall include:
(a) — a chemical and physical description, including the name under which a new
synthetic drug is known,
— information on the frequency, circumstances and/or quantities in which a new
synthetic drug is encountered,
— a first indication of the possible risks associated with the new synthetic drug,
and, as far as possible:
(b) — information on the chemical precursors,
— information on the mode and scope of the established or expected use of the
new synthetic drug as a psychotropic substance,
— information on other use of the new synthetic drug and the extent of such use,
— further information on the risks of use of the new synthetic drug, including the
health and the social risks.
Article 4
Risk assessment
1. At the request of one of the Member States or the Commission, the EMCDDA shall
convene a special meeting under the auspices of the Scientific Committee extended
with experts nominated by the Member States and to which representatives of the
Commission, the EDU and the European Agency for the Evaluation of Medicinal
Products shall be invited.
Joint action
This committee shall assess the possible risks, including the health and social risks,
caused by the use of, and traffic in, new synthetic drugs, and possible
consequences of prohibition.
2. The risk assessment shall be carried out on the basis of information provided by the
Member States, the Commission, the EMCDDA, the EDU of the European Agency
for the Evaluation of Medicinal Products and taking into account all factors which,
according to the 1971 United Nations Convention on Psychotropic Substances,
would warrant the placing of a substance under international control.
3. On completion of the risk assessment, a report will be drawn up on the findings. In
the report all aspects shall be addressed. All opinions on these aspects shall be
reflected in the report.
Article 5
Procedure for bringing specific new synthetic drugs under control
1. The Council may, on the basis of an initiative to be presented within a month from
the date on which the report of the results of the risk assessment pursuant to Article
4 (1) is established and acting in accordance with Article K.3(2)(b) of the Treaty,
adopt unanimously a decision defining the new synthetic drug or drugs which are
to be made subject to necessary measures of control.
If the Commission deems it not necessary to present an initiative to have the new
synthetic drug or drugs submitted to control measures, it shall present a report to
the Council explaining its views.
The Member States undertake, in accordance with the decision taken by the
Council, within such delay as that decision may specify, to take the necessary
measures in accordance with their national law to submit these new synthetic drugs
to control measures and criminal penalties as provided under their legislation
complying with their obligations under the 1971 United Nations Convention on
Psychotropic Substances with respect to substances listed in Schedules I or II
thereto.
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2. Nothing in this joint action shall prevent a Member State from maintaining or
introducing on its territory any national control measure it deems appropriate once
a new synthetic drug has been identified by a Member State.
3. The Presidency shall each year submit a report to the Council on the implementation
of the decisions adopted by the Council on the basis of paragraph 1.
Article 6
Publication and entry into force
This joint action shall be published in the Official Journal.
It shall enter into force on the day of its publication.
Done at Luxembourg, 16 June 1997.
For the Council
The President
H. VAN MIERLO
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
is one of the decentralised agencies set up by the European Union to carry
out specialised technical or scientific work.
Its role is to gather, analyse and disseminate objective, reliable and
comparable information on drugs and drug addiction and, in doing so,
provide its audiences with a sound and evidence-based picture of the drug
phenomenon at European level.
Among the Centre’s target groups are policy-makers who use this
information to help formulate coherent national and Community drug
strategies. Also served are professionals and researchers working in the
drugs field and, more broadly, the European media and general public. 
EMCDDA risk assessments are publications examining the health and social
risks of individual synthetic drugs on the basis of research carried out by
the agency and its partners.
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